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ABSTRACT

Discovery and Development of a Three-Component Oxidopyrylium Cycloaddition and Its
Application Towards α-Hydroxytropolone Synthesis
by
Michael P. D’Erasmo
Advisor: Professor Ryan P. Murelli
Historically, natural products have provided unique research opportunities and challenges
for organic synthesis, chemical biology, and medicinal chemistry due to their molecular
complexity and effects on physiological systems. The total synthesis of natural products has not
only produced novel reaction methods and strategies capable of efficiently generating complex
structural motifs but also granted access to sufficient quantities of otherwise scarce natural
product material for clinical evaluation. These synthetic efforts have facilitated the formation of
a transdisciplinary partnership between chemistry, biology, and medicine that has been
paramount in elucidating the chemical and pharmaceutical utility of natural products. Chapter I
of this thesis will highlight several key examples of how natural products inspired synthetic
methodology, small molecule drug and probe development, and the discovery of previously
unknown biologically active scaffolds. A particular focus will be spent on the synthetic and
biological endeavors made by our laboratory involving α-hydroxytropolones (αHTs).
αHTs are a subclass of troponoid natural products that possess promising activity
against a broad range of therapeutically significant targets. In order to gain access to these
molecules, our laboratory utilizes an oxidopyrylium cycloaddition/ring-opening strategy. During
our synthetic investigations, we recently discovered a three-component oxidopyrylium
cycloaddition that generates novel 8-oxabicyclo[3,2,1]octene products. In Chapter II, the
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development and optimization of this synthetic method towards the construction of a library of
new oxabicyclic species will be detailed. Initial attempts at applying the reaction towards αHT
synthesis will also be discussed, as a tandem debenzylation/ring-opening procedure with benzylderived oxabicyclic intermediates is outlined. Further exploration of the utility of the threecomponent oxidopyrylium cycloaddition will be described in Chapter III and Chapter IV, as
the first solid-phase and fluorous syntheses of αHTs are reported, respectively. The advantages
and disadvantages of each strategy will be considered in these chapters, specifically pertaining to
the efficiency of purification, incorporation/cleavage of solid-phase resins and fluorous tags, and
modification of supported intermediates.
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Chapter I
Exploring Nature’s Bounty: The Indispensable Partnership Between
Chemistry, Biology, and Medicine
1.1. Introduction
Investigating nature’s molecular diversity and its effects on physiological systems
continues to be a central area of advancement and cooperation for chemistry, medicine, and
biology.1 Each natural product class isolated and characterized possesses unique threedimensional construction and biological properties that introduces original research opportunities
and challenges.2 These compounds typically demonstrate structural domains very similar to
many human macromolecules, which provide intense pharmacological activity and selectivity. 2,3
Hence, natural products are by far the most abundant source of new small molecule drugs, 4 with
penicillin V (1.1, antibiotic), artemisinin (1.2, antimalarial), and galantamine (1.3, Alzheimer’s
treatment) being only a few examples (Figure 1.1). Additionally, such molecules have the
capability to efficiently modulate biomolecular function, making them exemplary probes to
systematically analyze cellular components, biochemical events, and signaling pathways.2,5
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1.2. (+)-Discodermolide: Total Synthesis Leading to Clinical Development
Historically, the total synthesis of natural products has brought about novel reaction
methods and technologies, innovative strategies for the rapid creation of complex structural
motifs, and a broad range of biologically active analogs derived from the targeted molecules. 2
Such breakthroughs have facilitated significant strides in the synthesis and modification of drugs
by enabling the production of sufficient quantities of scarce natural product material for clinical
development. As a result of these efforts by organic chemists, pharmaceutical endeavors
spanning both academia and industry emphasize the use of natural product isolation and organic
synthetic techniques in the design, generation, and testing of small molecule inhibitors and
chemical probes.1,2 This combination between organic synthesis and biology has unraveled
fundamental information on many physiological systems and established the standard for drug
discovery and development.
For example, (+)-discodermolide (1.4) is a polyketide natural product first isolated in
1990 by Gunasekera and co-workers from the Carribbean deep-sea marine sponge Discodermia
dissoluta.6 Similar to paclitaxel (1.5, Taxol®) and epothilones (1.6), the molecule inhibits
proliferation of cancer cells by stabilizing microtubules and arresting the cell cycle prior to
mitosis (Figure 1.2).7 Additionally, (+)-discodermolide possesses a number of other unique
biological characteristics, including immunosuppression both in vitro and in vivo, 8 potent
acceleration of cell aging,9 synergistic anticancer activity with paclitaxel, 10 and neuroprotective
effects.11 Due to its promising biological profile, the pharmaceutical industry was extremely
interested in clinically evaluating the natural product. However, since (+)-discodermolide
accounts for only 0.002 wt.% of D. dissoluta6 and all efforts to cultivate this organism failed,
material management restricted the advancement of biological studies. Such a supply dilemma
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made (+)-discodermolide an attractive target for total synthesis, and thus organic chemists sought
to develop a scalable synthetic route to generate its complex structure.
In 1993, Schreiber and co-workers described the first total synthesis of the unnatural
enantiomer (-)-discodermolide, which proved useful in establishing the absolute stereochemistry
of the natural product.12 After this study, a number of unique approaches emerged from academia
and industry detailing the synthesis of both discodermolide enantiomers.13 A retrosynthetic
analysis of these total syntheses reveals that all of them deconstruct the natural product into three
major fragments, each of which contain the contiguous methyl-hydroxyl-methyl array of
stereogenic centers present in the target molecule (Figure 1.3 for select examples). Various
strategies were then employed to couple the segments with the appropriate configuration and
stereochemistry, including the Nozaki-Hiyama-Kishi coupling/enol alkylation approach of
Schreiber,12,14 the Negishi coupling/Wittig olefination route of Smith, 15 and the novel chelationcontrolled aldol reactions of Paterson.16

3

As the synthetic research became more extensive, focus shifted towards making the
reaction sequences shorter, more convergent, and more practical in order to produce the material
demand required for clinical development. 13 Novartis Pharma AG took inspiration from these
methods and described a 39-step synthesis of 60 g of (+)-discodermolide in 2004 (Scheme
1.1).17 Specifically, Novartis integrated the Smith common precursor 1.18 to produce the three
major fragments and the Paterson aldol chemistry to connect the final segments together. The
material generated proved to be sufficient in advancing (+)-discodermolide to early-stage human
clinical trials. In addition, these synthetic developments facilitated the creation of a number of
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research programs aimed at the design, synthesis, and evaluation of (+)-discodermolide
analogs.13 Such efforts have uncovered the binding elements required for the natural product’s
biological profile and enabled the rational design of more potent anticancer agents through indepth structure-activity relationship (SAR) studies.
1.3. (-)-Diazonamide A: Chemical Probe Synthesis Elucidating Biological Pathways
Alongside its pivotal role in drug discovery, synthetic research geared towards the
assembly and modification of biologically interesting natural products has elucidated key
mechanistic

information on many physiological

processes through chemical

probe

development.1,2,18 For instance, (-)-diazonamide A (1.20, Figure 1.4), a compound isolated from
5

the colonial marine ascidian Diazona angulata, became an extremely popular target for organic
chemists and the pharmaceutical industry due to its intriguing molecular structure and potent
cytotoxicity against a variety of human cancer cell lines. 19 Early reports indicated that the
compound’s activity emerged from its microtubule-binding ability.20 However, other studies
contradicted this hypothesis, demonstrating that (-)-diazonamide A does not compete with
known tubulin-binding agents, such as maytansine (1.21) or vinblastine (1.22, Figure 1.4).21a
Thus, the race was on for a practical total synthetic route to access the molecule and its analogs
for biological evaluation.
By the late 1990s, nearly a dozen research groups dedicated efforts at efficiently
synthesizing (-)-diazonamide A.22 These ventures encountered a roadblock when Harran and coworkers in 2001 made the surprising discovery that the originally proposed structure for the
natural product had been misassigned based on their synthesis of 1.23 and 1.24 (Figure 1.5).23
Re-evaluation of the spectroscopic and crystallographic data acquired on (-)-diazonamides
revealed that the molecule actually possesses diarylaminal motifs instead of the phenolic
hemiacetals suggested from initial studies. Following these conclusions, attention was directed
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towards generating the new structure, as a number of total syntheses on diazonamide A would
emerge in the literature.22 However, the synthetic strategy that became the most relevant in the
clinical progression of diazonamides as chemotherapeutic agents would originate from Harran
and co-workers in 2003.24
The Harran 19-step approach to diazonamide A (1% overall yield) consisted of
constructing a seco-peptidyl precursor and installing the primary diarylaminal core through
oxidative annulation of the tethered tryptophan and tyrosine side chains (1.26 → 1.28, Scheme
1.2).24 Also, the atropisomerism in the eastern region of the molecule was established with a
photoinduced electron transfer reaction under basic conditions (1.29 → 1.32). Using this route to
assemble a biotinylated derivative, Harran, Wang, and co-workers disseminated the
mitochondrial enzyme, ornithine δ-amino transferase (OAT), as the biological target for the
natural product.21 These mechanistic studies also suggested that OAT serves an important
function in mitotic cell division, bringing to light a potential target for anticancer drug
development. More recently, the Harran synthetic method has been utilized and advanced in
collaboration with the pharmaceutical industry to produce detailed SAR studies on diazonamides
and potent antimitotic agents poised to enter clinical trials.25

7

1.4. Vancomycin and Teicoplanin: Confronting Chemical and Biological Challenges with
Synthetic Methodology
As outlined earlier, since physiologically active natural products are already equipped
with structural characteristics that efficiently bind to the domains of biological macromolecules,
they provide an ideal canvass for the semisynthesis of promising drug derivatives and chemical
probes.1,2,18 However, direct chemical alteration of natural products can be extremely difficult
due to the presence of multiple functional groups and stereogenic centers, which limit reaction
efficiency and selectivity. To address the challenge of natural product reactivity and the
increasing demand for SAR studies based on semisynthetic modification, sophisticated
developments on the synthetic methodology front have emerged. 2,26 In particular, site-selective
functionalization has become an effective tool in the synthesis of natural products and their
corresponding analogs.
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For example, Miller and co-workers have demonstrated the site-selective bromination of
the glycopeptide antibiotics, vancomycin (1.33) and teicoplanin (1.36), using peptide-based
catalysts.27 In the study involving vancomycin, the research group reported that the inherent
reactivity of the natural product towards halogenation can be controlled depending on the
additives present (Figure 1.6).27a On one hand, taking inspiration from the antibiotic’s natural
binding mode to bacterial cell walls,28 peptide 1.34 was designed and used to accelerate the
selective bromination of vancomycin at the 7f position. On the other hand, in order to reverse the
site of functionalization to the 7d position, guanidine-HCl (1.35) was the additive of choice
because of its capability to interact with the free carboxylate functionality and speed up
bromination reactions.29
Miller and co-workers would then apply these results to teicoplanin compound 1.36,
which possesses increased biological activity and molecular diversity compared to vancomycin
(Figure 1.7).27b Not only was peptide-dependent bromination at either the 5,7-biaryl or 1,3-biaryl
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ether sectors of the molecule achieved, but the group also performed Suzuki cross-coupling on
the brominated derivatives using aqueous conditions (i.e. Pd(OAc)2/sSPhos). This chemistry
enabled the direct synthesis of eleven novel teicoplanin analogs previously unavailable through
biosynthesis or total synthesis. Evaluation of the new compounds against a variety of bacterial
strains revealed comparable or increased activity in relation to vancomycin and teicoplanin.
Thus, the Miller site-selective bromination has the potential to grant access to a library of unique
natural product derived antibiotics useful against the rising threat of glycopeptide-resistant
bacteria.
1.5. γ-Hydroxybutenolides: New Chemical Entities Generated from Natural Product
Synthons
The progression and cooperation of organic synthesis, structural biology, and medicinal
chemistry has yielded technologies and methods to determine the primary components
responsible for the biological activity of natural products (i.e. pharmacophores). 1,2,18 As a result,
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considerable attention has been directed towards the development of synthetic methods capable
of preparing these structural moieties. Generally, these studies produce greatly simplified
analogs that mimic or exceed the function of the natural product from which they were
inspired.2,18 However, depending on the synthon’s reactivity, it is possible to generate completely
new chemical entities with promising pharmacological properties.
For instance, γ-hydroxybutenolides are heterocyclic motifs present in a variety of
biologically interesting natural products (Figure 1.8).30 These structures are readily synthesized
through the oxidation of furan31 and serve as synthetic precursors to elaborate lactone-containing
derivatives.32 Moreover, reports on γ-hydroxybutenolide reactivity have demonstrated that these
molecules actively engage in cascade and cycloaddition reactions 32 and act as intermediates in
natural product biosynthesis.33
1.5.1. The Discovery of Novel Spirocyclic Ketal-Lactones
Considering their ease of preparation and capability to form intricate constructs through
multi-bond forming processes, our laboratory further investigated γ-hydroxybutenolide
chemistry.34

These

studies,

conducted

by

Alberto

Munoz,

illustrated

that

γ-methyl-γ-hydroxybutenolide (1.40) reacts with aromatic aldehydes in the presence of triflate-
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based acids (e.g. triflic acid or trimethylsilyl triflate) to produce new spirocyclic ketal-lactones
(1.44, Scheme 1.3). An inspection of the substrate scope determined that electronically poor
aromatic aldehydes provide the highest yields (e.g. 1.44a-c), as more electron rich aromatic and
aliphatic species require large excesses of reagent to force conversion or lead to little or no
incorporation (1.44d-f). Lastly, γ-methyl-γ-hydroxybutenolide can be replaced with the γ-ethyl
derivative, supplying a molecule with 4 stereogenic centers (1.44g).
Our proposed mechanism for the process involves an elimination/Prins cascade, whereby
the lactone 1.41 forms in situ under acidic conditions and undergoes a reaction with 2 equiv. of
aldehyde to generate the spirocyclic ketal-lactones (Scheme 1.3). Butenolide 1.41 is also known
as protonanemonin, which is a toxic metabolite found in the Ranunculaceae plant family35 and
synthon that efficiently performs Diels-Alder and dipolar cycloaddition reactions.36 Supported by
NMR experiments and crystallographic data, the transformation demonstrates reversibility at the
steps that introduce relative stereochemistry and exhibits high diastereoselectivity that is
12

thermodynamically driven. Additionally, partial incorporation was observed after selected
spirocycles were re-subjected to reaction conditions with aromatic aldehydes, providing further
evidence for the reversibility of the process (Scheme 1.4).34
1.5.2. Biological Evaluation of Novel Spirocyclic Ketal-Lactones
With rapid access to a series of unprecedented spirocyclic diaryl butenolides that contain
an ‘extended ketal-lactone’ moiety present in many well-established bioactive molecules (Figure
1.9),37 we directed our attention towards assessing the pharmaceutical utility of the novel
constructs. In collaboration with the Bradner group, the compounds we generated were evaluated
for anticancer activity through a previously reported 48-hour viability assay.38 These experiments
uncovered that the butenolides illustrate potent cytotoxicity against a T-cell lymphoma cell line
(MJ) and a very aggressive epithelial cancer cell line (797 NUT midline carcinoma or NMC).
Moreover, the cytotoxic behavior of the molecules appears to be limited to mammalian cells, as
no noticeable growth inhibition was observed in Gram-negative bacteria assays.
13

Our structure-function study revealed that spirocyclic butenolides with electronwithdrawing functionalities on the phenyl appendages possessed the greatest potency (1.44a,
Figure 1.10). When the electron-withdrawing groups or the aromatic rings were removed, the
activity was severely reduced (1.44d, 1.44f). Diminished cytotoxicity also occurred when a
methyl substituent was added to the dioxane ring (1.44g). Additionally, when the size of the
aromatic appendages was extended, as shown with derivatives 1.44j and 1.44k, the inhibition
was negatively impacted. Thus, the information obtained illustrates that the spirocyclic
butenolide core is responsible for cytotoxicity, while the aromatic functionalities increase
potency. Though electron poor appendages yield the greatest inhibition, the activity is influenced
by a size restriction. Unfortunately, due to the limitations of the synthetic method outlined above,
a more diverse array of electronically rich aldehydes could not be examined.
We next tested if the pseudosymmetry of spirocyclic butenolides 1.44h and 1.44i had any
effect on biological activity (Figure 1.10). Despite differing merely in the position of the nitro
group, the compounds possessed nearly identical potency against the NMC and MJ carcinomas
and were approximately half as active as 1.44a. With regard to the binding mode of these
molecules, this data suggests that one aromatic ring does not have more control than the other.
14

Two possibilities emerge as a result: 1) the aromatic substituents work in combination during
binding or 2) one group is responsible for interacting but the pseudosymmetry of the molecules
makes each enantiomeric form roughly equivalent in potency. Our current methods do not allow
for the enantioenrichment of the spirocycles to prove which hypothesis is correct. Nonetheless,
efforts are currently being dedicated towards studying the mode in which the aromatic
appendages induce increased potency to the butenolide analogs.
Finally, we tested whether or not the electrophilic alkene on the butenolide core was
important to biological activity. Since α,β-unsaturated carbonyls frequently appear in covalent
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enzyme inhibitors,39 the possibility that the spirocyclic structures are covalent modifiers exists.
Therefore, compound 1.48b was synthesized by reducing 1.44b with Pd/C under a hydrogen
atmosphere (Scheme 1.5). The newly made molecule demonstrated no cytotoxicity, indicating
that the spirocyclic butenolides are covalent inhibitors.
In summary, natural product scaffolds can lead to new chemical entities with promising
physiological properties. Our laboratory has discovered a novel synthetic method to synthesize a
previously unknown class of spirocyclic ketal-lactones. Subsequently, we reported that these
molecules are potent cytotoxic agents against NMC797 and MJ carcinomas, outlining an indepth structure-function study on their biological activity.
1.6. α-Hydroxytropolones: Natural Product ‘Privileged Scaffolds’ Inspiring Clinically
Effective Drug Libraries
Many physiologically active natural products contain ‘privileged substructures’ that have
been molded by evolutionary processes to bind to a variety of receptors and enzymes.2,18,40
Coined by the Evans group in their 1988 pharmacological study of benzodiazepines, 41 a
‘privileged scaffold’ is applied to molecular constructs with the binding versatility and potential
to provide ligands for a wide range of biological macromolecules. It is surmised that these
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compounds achieve such promiscuous binding through mimicry of typical biomolecular surface
elements, such β- and γ-turns in proteins.40 Considering their synthesis and modification are
directed by physiological mechanisms and their function might involve completely different
cellular pathways, a plethora of natural product classes embody this concept (Figure 1.11 for
examples).
Due to their promising bioactivity, a number of research programs have dedicated efforts
at synthesizing compound libraries based on natural product-derived privileged structures.18,40
The strategies reported provide quick access to novel chemical entities through the alteration of a
central core framework and side-chain optimization. Additionally, the resulting privileged
constructs typically exhibit favorable drug-like characteristics, allowing for the discovery and
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development of new lead molecules for multiple receptors. For example, Nicolaou and coworkers have detailed the combinatorial synthesis of a 10,000-member benzopyran library using
a traceless phenylselenium resin.42 Biological studies on the compound collection revealed a
high hit rate, with some molecules inhibiting hypoxic activation of tumor growth. 43 Overall,
rational drug design based on privileged structures can be beneficial to the drug discovery
process and improve the effectiveness of biologically active species.
Our laboratory focuses on another privileged class of molecules, α-hydroxytropolones
(αHTs). These compounds are a subset of troponoid natural products that possess therapeutic
potential against a wide variety of biological targets (Figure 1.12).44 Pharmacological studies on
β-thujaplicinol (1.58) and manicol (1.59) have revealed that αHTs exhibit promising activity
against human immunodeficiency virus (HIV), 45 hepatitis B virus (HBV),46 herpes simplex virus
(HSV),47 and aminoglycoside resistant bacteria.48 Structurally, the molecules are defined by a
non-benzenoid aromatic ring system with a contiguous array of three oxygen atoms (1.60,
Figure 1.12B). Under basic conditions, this motif adopts a dianionic form (1.61), which can
further resonate to a stabilized tropylium ion with significant negative charge localized on the
oxygen assembly (1.62). Their promiscuous activity is generally attributed to the three
contiguous oxygen atoms, which can bind to and inhibit an assortment of dinuclear
metalloenzymes (represented by 1.62).44 The remaining positions on the αHT core can be
manipulated to increase enzymatic potency and selectivity. Thus, αHTs are appealing scaffolds
for developing new drug leads against several therapeutically challenging diseases.
1.6.1. Oxidopyrylium Cycloaddition/Ring-Opening Route to αHTs
Despite the promising inhibitory profile of this natural product class, the number of
synthetic methods available to access αHTs and SAR studies probing their bioactivity is
lacking.44 Motivated by the deficiency in synthetic and medicinal chemistry developments, our
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laboratory invented a strategy to generate di- and trisubstituted αHT analogs utilizing
8-oxabicyclo[3,2,1]octene intermediates (1.66, Scheme 1.6).49 In the two-phase approach, a
3-hydroxy-4-pyrone-based oxidopyrylium cycloaddition gives the oxabicyclic compounds,
which further undergo acid-mediated ring opening to αHTs (1.68). Among the advantages of our
synthetic route are the use of readily available alkynes (1.65) and the facile introduction of
structural diversity to the αHT core. Moreover, triflate salt 1.64, a key component of the
oxidopyrylium cycloaddition step, can be made on a large-scale from kojic acid (1.63), which is
a very cheap skin-bleaching agent and a by-product of rice fermentation during sake
production.50
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Our synthetic method also grants access to more structurally complex αHTs through
modification of the various reagents and intermediates. For instance, a series of ketonecontaining αHTs 1.68a-d was synthesized by initially performing oxidopyrylium cycloadditions
between triflate salt 1.64a and ynone derivatives (1.70, Scheme 1.7). The ynones were generated
using a previously described procedure, whereby the analogous acyl chlorides (1.69) are reacted
with TMS acetylene in the presence of AlCl 3.51 The resulting oxabicyclic compounds (1.66a-d)
were then subjected to acid-mediated ring-opening/demethylation to yield the final products.
1.6.2. Structure-Function Studies with Synthetic αHTs
With this route in hand, our group was able to synthesize a sizable library of over 60
αHTs and execute SAR studies on various pharmacological targets. In collaboration with several
labs, we tested the compounds against HIV reverse transcriptase ribonuclease H (RNase H),52
HBV RNase H,53 HSV-associated enzymes,54 aminoglycoside-2”-O-nucleotidyltransferase
(ANT(2”),55 and fungal pathogens.56 These biological studies present in-depth inhibitory
information on the collection of αHTs, including the ketone-containing derivatives outlined in
Scheme 1.7 (Table 1.1). However, the current discussion will focus on the significant HSVrelated discoveries made with the ketone-containing derivatives.54
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HSV-1 and HSV-2 are highly related and ubiquitous human pathogens that have infected
over half a billion individuals worldwide.47,54,57 The herpesviruses chronically infect mucosal
surfaces and abraded skin and maintain a lifelong latency, whereby periodic reactivation of viral
replication results in recurrent and transmissible diseases. HSV-1 is generally associated with
cold sores, a rare form of encephalitis, and corneal blindness, while HSV-2 leads to genital
ulcerative disease. In order to treat acute infections or reduce viral replication, nucleoside analog
drugs such as acyclovir (ACV) are employed. 47,54,57,58 However, the treatments are incompletely
effective, and the emergence of drug-resistant viral variants is becoming an increasing threat,
especially for immunocompromised patients. 47,54,57,59 Thus, new molecules are required to
achieve more efficient suppression of HSV.
HSV genomic replication relies upon numerous processes typically catalyzed by
enzymes in the nuleotidyltransferase superfamily (NTS). 47,54 These enzymes perform many
functions in nucleic acid metabolism, including DNA and RNA digestion and DNA repair,
integration and recombination. The NTS contains dinuclear metalloproteins, such as Human
RNase H, HBV RNase H, HIV RNase H, and HIV integrase. 47,54,60 Within their active sites, the
enzymes possess three or four conserved carboxylates that coordinate two divalent cations
pivotal for nucleic acid cleavage (Figure 1.13 for example). Tavis et al. demonstrated that
compounds with the capability to suppress these enzymes, including β-thujaplicinol and manicol,
could also inhibit wild-type and ACV-resistant HSV-1 and HSV-2 replication in cell culture.47 In
collaboration with Tavis, Morrison, and co-workers, our laboratory then tested a series of αHTs
against HSV to assess their viability as drug candidates.54b The most potent molecule to emerge
from the study was 1.68d, which exhibited nanomolar (nM) inhibition in HSV replication assays
and displayed a synergistic therapeutic effect with ACV (Figure 1.14).

21

Subsequently, studies were conducted in order to identify the binding target for 1.68d.
Based on NTS activity and homology, the αHT analog could interact with several possible HSV
enzymes.47,54 One option is the pUL15 terminase, which is an end-stage RNase H-like divalent
metalloprotein responsible for mobilizing viral DNA into the capsid. 61 Inhibition and thermal
stabilization experiments conducted in collaboration with Le Grice and co-workers illustrate that
1.68d weakly binds to pUL15, indicating that the enzyme might not be the primary target of
action.54a A second choice is the exonuclease pUL12, which plays a role in DNA recombination
earlier in the replication process.62 Initial experiments conducted with Weller and co-workers
demonstrate that 1.68d interacts with pUL12. However, more data is required in order to obtain a
complete mechanistic understanding.54c
In summary, many natural product classes possess ‘privileged scaffolds’ that can interact
with various therapeutically significant biomacromolecules. Designing compound libraries based
on these privileged substructures has the potential to produce drug leads for multiple targets. 18,40
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Our laboratory has dedicated efforts towards synthesizing and biologically assessing αHTs,
which bind to and inhibit an assortment of dinuclear metalloenzymes. 49,52-56 During our
screening of a 60 αHT library against a number of viral targets, we discovered the very potent
HSV inhibitor 1.68d.54 Thus far, mechanistic studies have not fully elucidated the primary mode
of action for the αHT derivative. However, biological studies aimed at identifying the viral target
are currently ongoing.
1.7. Conclusion
The drive to understand the structural complexity and physiological effects of natural
products has led to incredible advancements across scientific disciplines. While exploring the
chemistry of γ-hydroxybutenolides, a heterocyclic motif present in many biologically active
molecules, our laboratory has discovered a synthetic method to access novel spirocyclic ketal
lactones with potent cytotoxicity against the MJ T-cell lymphoma and NMC797 epithelial cancer
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cell lines. Moreover, our group has invented a two-phase approach to generate
α-hydroxytropolones, which are natural product-derived privileged substructures that possess
activity against a wide range of therapeutically viable targets. This route has allowed us to
construct a library of αHTs for several medicinal chemistry studies. Out of these efforts, we have
reported highly potent synthetic analogs. One such example is 1.68d, a promising drug candidate
with intense cellular activity against HSV. Utilizing this synthetic method, our laboratory
continues to produce αHT analogs for pharmacological examination. The remainder of this thesis
will highlight advancements made towards αHT synthesis. Specifically, herein will be described
the discovery and development of a new three-component oxidopyrylium cycloaddition, and its
application in the first solid-phase and fluorous-supported syntheses of αHTs.
1.8. Experimental and Supporting Information
General Information: All starting materials and reagents were purchased from commercially
available sources and used without further purification, with exception of CH2Cl2, which was
purified on a solvent purification system prior to reactions. 63 1H NMR shifts are measured using
the solvent residual peak as the internal standard (CHCl 3 δ 7.26), and reported as follows:
chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet
of doublet, q = quartet, m = multiplet), coupling constant (Hz), integration.
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C NMR shifts are

measured using the solvent residual peak as the internal standard (CDCl 3 δ 77.16), and reported
as chemical shifts. Infrared (IR) spectral bands are characterized as broad (br), strong (s),
medium (m), and weak (w). Mass spectra were recorded on a spectrometer by electrospray
ionization (ESI) technique and time-of-flight (TOF) mass analyzer. Microwave reactions were
performed via the Biotage® Intiator (External IR Temperature Sensor). Where noted, reaction
products were purified via silica gel chromatography using a Biotage ® Isolera Prime, with
Biotage® SNAP 10 g cartridges, in a solvent system of ethyl acetate (EtOAc) in hexane.
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Synthesis of Spirocyclic Ketal-Lactones:
(5S,7R,9S)-7,9-bis(perfluorophenyl)-1,6,8-trioxaspiro[4.5]dec-3-en-2-one (1.44j).

To a

solution of γ-hydroxybutenolide 1.40 (40 mg, 0.35 mmol) and pentafluorobenzaldehyde (866 μL,
7.0 mmol, 20 equiv.) in CH2Cl2 (0.2 M, 1.75 mL) over 3Å molecular sieves (8 pellets) was
added trimethylsilyltriflate (126 μL, 0.7 mmol, 2 equiv.). The reaction mixture was stirred for
3 h, after which time Et3N (8 drops) was added. The reaction mixture was then immediately
purified by column chromatography (silica (10 g), 2% EtOAc/hexane to 15% EtOAc/hexane
gradient over 32 column volumes), giving 1.44j as a pale yellow oil (95.0 mg, 56% yield).
Rf = 0.21 in 10% EtOAc in hexanes. IR (thin film, KBr): 3109 (w), 2935 (w), 2855 (w), 1787
(s), 1657 (m), 1526 (s), 1514 (s), 1420 (m), 1304 (m), 1169 (s), 1139 (s), 1061 (m), 1017 (s), 976
(s), 888 (m), 788 (m) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.29 (d, J = 5.6 Hz, 1H), 6.61
(s, 1H), 6.30 (d, J = 5.6 Hz, 1H), 5.74 (dd, J = 12.2, 2.3 Hz, 1H), 2.92 (t, J = 12.8 Hz, 1H), 1.93
(dd, J = 13.4, 2.5 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ 168.8 (s), 152.0 (s), 147.0 – 146.4
(m), 144.6 – 144.0 (m), 143.9 – 142.8 (m), 141.6 – 140.2 (m), 139.5 – 138.6 (m), 137.0 – 136.2
(m), 124.7 (s), 112.1 – 111.5 (m), 110.7 – 110.2 (m), 105.1 (s), 92.0 (s), 67.6 (s), 35.2 (s).
HRMS (ESI+): m/z calc’d for C19H6F10O4Na+: 510.9999. Found: 511.0011.
(5S,7R,9S)-7,9-bis(1-nitronaphthalen-2-yl)-1,6,8-trioxaspiro[4.5]dec-3-en-2-one (1.44k). To
a solution of γ-hydroxybutenolide 1.40 (20 mg, 0.175 mmol) and 1-nitro-2-naphthaldehyde
(211.2 mg, 1.05 mmol, 6 equiv.) in CH2Cl2 (0.2 M, 875 μL) over 3Å molecular sieves (4 pellets)
was added trimethylsilyltriflate (63 μL, 0.35 mmol, 2 equiv.). The reaction mixture was stirred
for 1.5 h, after which time Et3N (4 drops) was added. The reaction mixture was then immediately
purified by column chromatography (silica (10 g), 10% EtOAc/hexane to 33% EtOAc/hexane
gradient over 30 column volumes), giving 1.44k as a brown oil (27.3 mg, 31% yield). Rf = 0.23
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in 30% EtOAc in hexanes. IR (thin film, KBr): 3099 (w), 3066 (w), 2929 (w), 2877 (w), 1781
(s), 1531 (s), 1359 (m), 1344 (m), 1200 (m), 1161 (m), 1140 (m), 1079 (w), 913 (m), 868 (w),
822 (m), 731 (m) cm-1. 1H NMR (400 MHz, CDCl3): δ 8.05 (dd, J = 12.0, 8.7 Hz, 2H),
7.98 – 7.87 (m, 2H), 7.82 – 7.71 (m, 4H), 7.69 – 7.58 (m, 4H), 7.23 (d, J = 5.6 Hz, 1H), 6.63
(s, 1H), 6.29 (d, J = 5.6 Hz, 1H), 5.63 (dd, J = 11.6, 2.2 Hz, 1H), 2.57 – 2.45 (m, 1H), 2.20
(dd, J = 13.6, 2.4 Hz, 1H).
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C NMR (100 MHz, CDCl3): δ 169.0, 151.8, 146.8, 146.1, 134.4,

133.7, 131.9, 131.0, 129.2, 129.1, 128.8, 128.4, 128.2, 128.2, 128.1, 125.2, 124.8, 124.5, 124.4,
123.5, 123.1, 122.3, 122.1, 105.1, 95.8, 72.8, 38.3. HRMS (ESI+): m/z calc’d for C27H19N2O8+:
499.1136. Found: 499.1139.
(5R,7R,9S)-7,9-bis(3-(trifluoromethyl)phenyl)-1,6,8-trioxaspiro[4.5]decan-2-one (1.48b).
To an argon degassed solution of 1.44b (46.9 mg, 0.105 mmol) in MeOH (0.09 M, 1.2 ml) was
added palladium on carbon (11.2 mg, 0.105 mmol, 1 equiv.). The reaction mixture was equipped
with a balloon of H2(g), stirred for 2 h at room temperature, and placed through a pad of Celite ®.
The reaction mixture was then purified by column chromatography (Silica (10 g), 2%
EtOAc/hexanes to 25% EtOAc/hexanes gradient over 22 column volumes), giving 1.48b as a
colorless oil (21.6 mg, 46% yield). Rf = 0.31 in 20% EtOAc in hexanes. IR (thin film, KBr):
3075 (w), 2956 (w), 2927 (w), 2854 (w), 1790 (s), 1379 (w), 1329 (s), 1209 (s), 1166 (s), 1124
(s), 1074 (s), 1017 (w), 902 (m), 870 (m), 801 (m), 702 (m) cm -1. 1H NMR (400 MHz, CDCl3):
δ 7.81 (s, 1H), 7.76 – 7.49 (m, 7H), 6.22 (s, 1H), 5.36 (t, J = 7.2 Hz, 1H), 2.96 – 2.83 (m, 1H),
2.63 (dd, J = 17.0, 8.7 Hz, 1H), 2.52 – 2.44 (m, 1H), 2.31 – 2.15 (m, 3H). 13C NMR (100 MHz,
CDCl3): δ 175.5 (s), 141.1 (s), 138.0 (s), 132.0 – 130.4 (m), 130.1 (s), 129.4 (s), 129.3 (s), 129.1
(s), 126.4 (d, J = 3.7 Hz), 125.5 (s), 125.3 (d, J = 3.8 Hz), 123.7 – 123.4 (m), 122.7
(d, J = 4.0 Hz), 106.3 (s), 96.1 (s), 75.2 (s), 40.9 (s), 34.6 (s), 27.7 (s). HRMS (ESI+): m/z calc’d
for C21H16 F6O4Na+: 469.0845. Found: 469.0853.
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Synthesis of 3-Methoxy-8-oxabicyclo[3.2.1]octenes:
6-isobutyryl-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (1.66a). Triflate salt
1.64a (258.3 mg, 0.890 mmol), N,N-diisopropylaniline (433 μL, 2.23 mmol, 2.5 equiv.),
4-methylpent-1-yn-3-one (427.6 mg, 4.45 mmol, 5 equiv.), and CDCl3 (0.15 M, 6 mL) were
placed in a sealed tube reactor (Biotage ® microwave reaction vial, 2-5 mL), and the reaction
mixture was subjected to microwave irradiation at 100 °C for 45 min. The reaction mixture was
then immediately purified by column chromatography (silica (10 g), 2% EtOAc/hexane to 35%
EtOAc/hexane gradient over 48 column volumes), giving 1.66a as a yellow oil (148.1 mg, 70%
yield). Rf = 0.34 in 20% EtOAc in hexanes. IR (thin film, KBr): 3082 (w), 2974 (m), 2936 (w),
1713 (s), 1671 (s), 1610 (s), 1459 (w), 1383 (m), 1343 (m), 1291 (m), 1213 (m), 1180 (m), 1128
(s), 1048 (m), 989 (m), 873 (w) cm-1. 1H NMR (400 MHz, CDCl3): δ 6.93 (d, J = 2.2 Hz, 1H),
6.06 (s, 1H), 4.98 (d, J = 2.4 Hz, 1H), 3.46 (s, 3H), 3.02 (sept, J = 6.9 Hz, 1H), 1.61 (s, 3H), 1.07
(d, J = 7.1 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H).
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C NMR (100 MHz, CDCl3): δ 201.3, 188.8,

155.5, 144.9, 136.7, 119.8, 86.2, 85.9, 54.6, 37.9, 21.0, 19.5, 17.6. HRMS (ESI+): m/z calc’d for
C13H17O4+: 237.1121. Found: 237.1124.
6-(cyclohexanecarbonyl)-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one
(1.66b). Triflate salt 1.64a (94 mg, 0.324 mmol), N,N-diisopropylaniline (75.7 μL, 0.389 mmol,
1.2 equiv.), 1-cyclohexylprop-2-yn-1-one (220.5 mg, 1.62 mmol, 5 equiv.), and CHCl 3 (0.16 M,
2 mL) were placed in a sealed tube reactor (Biotage ® microwave reaction vial, 2-5 mL), and the
reaction mixture was subjected to microwave irradiation at 100 °C for 45 min. The reaction
mixture was then immediately purified by column chromatography (silica gel, 18 cm x 1.8 cm,
solvent gradient: 5% EtOAc in hexanes (100 mL); 10% EtOAc in hexanes (100 mL); 20%
EtOAc in hexanes (200 mL); 30% EtOAc in hexanes (100 mL)), giving 1.66b as a yellow oil
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(78.2 mg, 87% yield). Rf = 0.24 in 15% EtOAc in hexanes. IR (thin film, KBr): 3063 (w), 2928
(m), 2853 (m), 1709 (s), 1667 (s), 1609 (s), 1450 (m), 1444 (m), 1337 (m), 1263 (m), 1179 (m),
1128 (s), 1046 (m), 987 (m), 866 (m), 738 (s) cm-1.1H NMR (400 MHz, CDCl3): δ 6.91
(d, J = 2.5 Hz, 1H), 6.05 (s, 1H), 4.97 (d, J = 2.6 Hz, 1H), 3.45 (s, 3H), 2.72 (ddd, J = 11.2, 7.2,
3.4 Hz, 1H), 1.85 – 1.61 (m, 5H), 1.59 (s, 3H), 1.47 – 1.06 (m, 5H).
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C NMR (100 MHz,

CDCl3): δ 200.7, 188.8, 155.5, 144.9, 136.5, 119.9, 86.2, 85.9, 54.6, 48.0, 29.9, 27.7, 25.8, 25.7,
25.1, 21.0. HRMS (ESI+): m/z calc’d for C16H21O4+: 277.1434. Found: 277.1439.
6-(2-cyclohexylacetyl)-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (1.66c).
Triflate salt 1.64a (100 mg, 0.345 mmol), N,N-diisopropylaniline (80.6 μL, 0.414 mmol,
1.2 equiv.), 1-cyclohexylbut-3-yn-2-one (258 mg, 1.72 mmol, 5 equiv.), and CH2Cl2 (0.16 M,
2.2 mL) were placed in a sealed tube reactor (Biotage® microwave reaction vial, 2-5 mL), and
the reaction mixture was subjected to microwave irradiation at 100 °C for 35 min. The reaction
mixture was then immediately purified by column chromatography (silica (10 g), 2%
EtOAc/hexane to 35% EtOAc/hexane gradient over 46 column volumes), giving 1.66c as a
yellow oil (68.1 mg, 67% yield). Rf = 0.20 in 15% EtOAc in hexanes. IR (thin film, KBr): 3081
(w), 2924 (s), 2851 (s), 1713 (s), 1668 (s), 1609 (s), 1449 (m), 1342 (m), 1303 (w), 1190 (m),
1178 (m), 1127 (s), 1048 (m), 987 (m), 869 (m), 773 (w) cm-1. 1H NMR (400 MHz, CDCl3): δ
6.96 (d, J = 2.3 Hz, 1H), 6.07 (s, 1H), 5.01 (d, J = 2.4 Hz, 1H), 3.50 (s, 3H), 2.55 (dd, J = 15.3,
6.5 Hz, 1H), 2.44 (dd, J = 15.3, 7.3 Hz, 1H), 1.88 – 1.75 (m, 1H), 1.67 (s, 3H), 1.72 – 1.54
(m, 5H), 1.30 – 1.02 (m, 3H), 1.00 – 0.80 (m, 2H).
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C NMR (100 MHz, CDCl3): δ 197.2,

189.0, 156.8, 145.1, 137.7, 119.8, 86.2, 85.9, 54.7, 47.9, 34.7, 33.4, 33.2, 26.2, 26.1, 26.1, 21.3.
HRMS (ESI+): m/z calc’d for for C17H23O4+: 291.1591. Found: 291.1593.
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6-([1,1'-Biphenyl]-4-carbonyl)-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one
(1.66d). Triflate salt 1.64a (100 mg, 0.345 mmol), N,N-diisopropylaniline (81 μL, 0.414 mmol,
1.2 equiv.), 1-([1,1'-biphenyl]-4-yl)prop-2-yn-1-one (712 mg, 3.45 mmol, 10 equiv.), and CH2Cl2
(0.07 M, 5 mL) were placed in a sealed tube reactor (Biotage ® microwave reaction vial,
10-20 mL), and the reaction mixture was subjected to microwave irradiation at 100 °C for 1 h.
The reaction mixture was then immediately concentrated and purified by column
chromatography (silica (10 g), 0% EtOAc/hexane to 35% EtOAc/hexane gradient over
20 column volumes), giving 1.66d as an orange solid (92.8 mg, 77% yield). MP = 156-159 °C.
Rf = 0.22 in 20% EtOAc in hexanes. IR (thin film, KBr): 3063 (w), 2979 (w), 2935 (w), 2837
(w), 1711 (s), 1641 (m), 1603 (s), 1449 (w), 1323 (m), 1228 (w), 1127 (m), 1043 (w), 989 (w),
844 (m), 744 (s), 698 (m) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.93 (d, J = 8.3 Hz, 2H), 7.71
(d, J = 8.3 Hz, 2H), 7.65 – 7.61 (m, 2H), 7.51 – 7.39 (m, 3H), 6.83 (d, J = 2.4 Hz, 1H), 6.30
(s, 1H), 5.20 (d, J = 2.5 Hz, 1H), 3.60 (s, 3H), 1.77 (s, 3H).
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C NMR (100 MHz, CDCl3): δ

190.2, 188.5, 155.1, 146.5, 145.1, 139.6, 138.6, 135.5, 129.7, 129.1, 128.5, 127.4, 127.3, 120.4,
87.2, 86.8, 54.8, 20.9. HRMS (ESI+): m/z calc’d for C22H19O4+: 347.1278. Found: 347.1280.
Synthesis of α-Hydroxytropolones:
2,7-dihydroxy-4-isobutyryl-5-methylcyclohepta-2,4,6-trien-1-one (1.68a). To a solution of
bicycle 1.66a (31.8 mg, 0.127 mmol) in CH2Cl2 (1.5 M, 86.7 μL) was added triflic acid (45.0 μL,
0.507 mmol, 4 equiv.). The reaction mixture was allowed to stir for 30 min, after which time it
was quenched with sodium acetate (98 mg, 1.20 mmol, 10 equiv.), stirred for 20 min, and
concentrated under reduced pressure. The crude mixture was then dissolved in 25% HBr in
acetic acid (4 mL), and heated to 90 ºC for 4 h.The reaction mixture was cooled to room
temperature, quenched with phosphate buffer (pH 7, 10 mL), and diluted with CH2Cl2 (5 mL).
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The organic layer was washed with phosphate buffer (pH 7, 3 x 10 mL), dried over Na2SO4,
filtered, and concentrated to give 1.68a as a brown oil (21.7 mg, 77% yield). IR (thin film,
KBr): 3261 (br), 2971 (w), 2933 (w), 2873 (w), 1701 (m), 1538 (m), 1465 (m), 1397 (m), 1384
(m), 1282 (m), 1189 (m), 1147 (w), 1092 (w), 904 (w), 826 (w), 729 (w) cm -1. 1H NMR
(400 MHz, CDCl3): δ 7.47 (s, 1H), 7.28 (s, 1H), 3.14 (sept, J = 6.9 Hz, 1H), 2.38 (s, 1H), 1.21
(d, J = 6.9 Hz, 1H).
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C NMR (50 MHz, CDCl3): δ 210.3, 168.2, 158.8, 157.3, 141.5, 137.8,

124.8, 118.1, 40.7, 24.6, 18.2. HRMS (ESI+): m/z calc’d for C12H15O4+: 223.0965. Found:
223.0965.
4-(cyclohexanecarbonyl)-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trienone (1.68b). To a
solution of bicycle 1.66b (35.1 mg, 0.121 mmol) in CH2Cl2 (95.3 μL) was added triflic acid
(43.0 μL, 0.486 mmol, 4 equiv.). The reaction mixture was allowed to stir for 30 min, after
which time it was quenched with sodium acetate (99 mg, 1.21 mmol, 10 equiv.), stirred for
20 min, and concentrated under reduced pressure. The crude mixture was then dissolved in 25%
HBr in acetic acid (2 mL) and heated to 90 ºC for 4 h. The reaction mixture was cooled to room
temperature, quenched with phosphate buffer (pH 7, 10 mL), and diluted with CH2Cl2 (5 mL).
The organic layer was washed with phosphate buffer (pH 7, 3 x 10 mL), dried over Na2SO4,
filtered, and concentrated to give 1.68b as a black oil (26.6 mg, 84% yield). IR (thin film, KBr):
3262 (br), 2930 (s), 2854 (s), 1698 (m), 1538 (s), 1449 (s), 1395 (m), 1281 (s), 1233 (s), 1193
(s), 1160 (w), 1089 (w), 1030 (w), 958 (w), 906 (w), 731 (w) cm-1. 1H NMR (400 MHz,
CDCl3): δ 7.46 (s, 1H), 7.28 (s, 1H), 2.89 – 2.76 (m, 1H), 2.37 (s, 3H), 1.98 – 1.65 (m, 5H),
1.51 – 1.16 (m, 5H). 13C NMR (100 MHz, CDCl3): δ 209.6, 168.2, 158.7, 157.2, 141.7, 137.8,
124.7, 118.1, 50.6, 28.6, 25.8, 25.8, 24.6. HRMS (ESI+): m/z calc’d for C15H19O4+: 263.1278.
Found: 263.1283.
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4-(2-cyclohexylacetyl)-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trienone (1.68c). To a
solution of bicycle 1.66c (31.2 mg, 0.103 mmol) in CH2Cl2 (0.11 M, 900 μL) was added triflic
acid (37.0 μL, 0.413 mmol, 4 equiv.). The reaction mixture was allowed to stir for 30 min, after
which time it was quenched with sodium acetate (85 mg, 1.03 mmol, 10 equiv.), stirred for
20 min, and concentrated under reduced pressure. The crude mixture was then dissolved in 25%
HBr in acetic acid (2 mL) and heated to 90 ºC for 4 h. The reaction mixture was cooled to room
temperature, quenched with phosphate buffer (pH 7, 10 mL), and diluted with CH2Cl2 (5 mL).
The organic layer was washed with phosphate buffer (pH 7, 3 x 10 mL), dried over Na2SO4,
filtered, and concentrated to give 1.68c as a brown oil (23.3 mg, 82% yield). IR (thin film,
KBr): 3255 (br), 2924 (s), 2852 (m), 1704 (m), 1538 (s), 1448 (m), 1397 (m), 1351 (m), 1280
(s), 1208 (s), 1156 (m), 1115 (m), 1090 (w), 906 (w), 785 (w), 733 (w) cm-1. 1H NMR
(400 MHz, CDCl3): δ 7.46 (s, 1H), 7.27 (s, 1H), 2.67 (d, J = 6.7 Hz, 2H), 2.40 (s, 3H),
2.06 – 1.94 (m, 1H), 1.84 – 1.61 (m, 5H), 1.38 – 0.93 (m, 5H). 13C NMR (50 MHz, CDCl3): δ
206.1, 168.1, 158.8, 157.4, 142.3, 137.4, 125.0, 118.1, 50.9, 33.6, 33.4, 26.3, 26.2, 24.4. HRMS
(ESI+): m/z calc’d for C16H21O4+: 277.1434. Found: 277.1441.
4-([1,1'-biphenyl]-4-carbonyl)-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trien-1-one (1.68d).
To a solution of bicycle 1.66d (46.4 mg, 0.134 mmol) in CH2Cl2 (0.09 M, 1.5 mL) was added
trifluoromethanesulfonic acid (47.3 μL, 0.536 mmol, 4 equiv.). The reaction mixture was
allowed to stir for 30 min, after which time it was quenched with sodium acetate (110 mg,
1.34 mmol, 10 equiv.), stirred for 20 min, and concentrated under reduced pressure. The crude
mixture was then dissolved in 25% HBr in acetic acid (2 mL), and heated to 90 ºC for 4 h. The
reaction mixture was cooled to room temperature, quenched with phosphate buffer (pH 7,
10 mL), and diluted with CH2Cl2 (5 mL). The organic layer was washed phosphate buffer (pH 7,
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3 x 10 mL), dried over Na2SO4, filtered, and concentrated to give 1.68d as a brown oil (26.2 mg,
59% yield). IR (thin film, KBr): 3262 (br), 3060 (w), 2961 (w), 1669 (s), 1601 (s), 1534 (s),
1398 (m), 1284 (s), 1232 (s), 1191 (s), 1083 (s), 1007 (m), 906 (m), 859 (m), 750 (s), 696 (m)
cm-1. 1H NMR (400 MHz, CDCl3): δ 7.88 (d, J = 8.2 Hz, 2H), 7.71 (d, J = 8.2 Hz, 2H), 7.63
(d, J = 7.4 Hz, 2H), 7.54 (s, 1H), 7.52 – 7.39 (m, 3H), 7.36 (s, 1H), 2.36 (s, 3H).
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C NMR

(100 MHz, CDCl3): δ 196.8, 168.5, 158.8, 157.1, 147.3, 140.0, 139.7, 138.2, 134.4, 130.9,
129.2, 128.8, 127.8, 127.5, 124.5, 119.0, 24.7. HRMS (ESI+): m/z calc’d for C21H17O4+:
333.1121. Found: 333.1124.
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Figure 1.15. 1H NMR spectrum of compound 1.44j in CDCl3.
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Figure 1.16. 13C NMR spectrum of compound 1.44j in CDCl3.
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Figure 1.17. 1H NMR spectrum of compound 1.44k in CDCl3.
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Figure 1.18. 13C NMR spectrum of compound 1.44k in CDCl3.
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Figure 1.19. 1H NMR spectrum of compound 1.48b in CDCl3.
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Figure 1.20. 13C NMR spectrum of compound 1.48b in CDCl3.
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Figure 1.21. 1H NMR spectrum of compound 1.66a in CDCl3.
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Figure 1.22. 13C NMR spectrum of compound 1.66a in CDCl3.
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Figure 1.23. 1H NMR spectrum of compound 1.66b in CDCl3.

41

Figure 1.24. 13C NMR spectrum of compound 1.66b in CDCl3.
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Figure 1.25. 1H NMR spectrum of compound 1.66c in CDCl3.
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Figure 1.26. 13C NMR spectrum of compound 1.66c in CDCl3.
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Figure 1.27. 1H NMR spectrum of compound 1.66d in CDCl3.
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Figure 1.28. 13C NMR spectrum of compound 1.66d in CDCl3.
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Figure 1.29. 1H NMR spectrum of compound 1.68a in CDCl3.
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Figure 1.30. 13C NMR spectrum of compound 1.68a in CDCl3.
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Figure 1.31. 1H NMR spectrum of compound 1.68b in CDCl3.
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Figure 1.32. 13C NMR spectrum of compound 1.68b in CDCl3.

50

Figure 1.33. 1H NMR spectrum of compound 1.68c in CDCl3.
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Figure 1.34. 13C NMR spectrum of compound 1.68c in CDCl3.
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Figure 1.35. 1H NMR spectrum of compound 1.68d in CDCl3.
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Figure 1.36. 13C NMR spectrum of compound 1.68d in CDCl3.
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Chapter II
The Discovery and Development of a Three-Component Oxidopyrylium
Cycloaddition
2.1. Analyzing the Oxidopyrylium Cycloaddition/Ring-Opening Route to αHTs
2.1.1. Synthetic Method Limitations
As reviewed in the previous chapter, our laboratory has reported an oxidopyrylium
cycloaddition/acid-mediated ring-opening approach to gain access to polysubstituted αHTs
(Scheme 2.1).49 This strategy has allowed us to construct a sizable library of over 60 derivatives
that have been dedicated to medicinal chemistry studies for several therapeutically significant
targets.52-56 Nevertheless, the synthetic method is not without limitation in regards to SAR and
chemical probe development. Specifically, the strongly acidic demethylation conditions required
for conversion of 2.5 to 2.6 prevent the introduction of a wide range of pharmacologically
relevant functional groups (e.g. many amides, esters, amines, etc.)64 and activity-based probes
and linkers (e.g. diazarines and pegylated biotin) 65 to the αHT scaffold (Figure 2.1).
Demethylation generally necessitates harsh reagents and procedures that are not functional group
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tolerant, including boron tribromide (BBr3) and HBr/AcOH or LiCl/DMSO at high
temperatures.66 Thus, in order to address the restrictions on αHT design, the final step of our
route must be bypassed.
2.1.2. 3-Hydroxy-4-Pyrone-Based Oxidopyrylium Cycloadditions and Their Origins
To carry out this task, we must first understand the importance of the methoxy
functionality to the overall αHT synthesis. The incorporation of the methyl ether that requires
deprotection at the end of Scheme 2.1 occurs during the formation of triflate salt 2.2. The
methoxy group enables the following intermolecular [5 + 2] cycloaddition reaction between 2.2
and alkynes (2.3) in the presence of base to produce the oxabicyclic intermediates (2.4). Also
classified as

a

3-hydroxy-4-pyrone-based

oxidopyrylium

cycloaddition,

this

process

mechanistically entails the generation of an oxidopyrylium ylide as the reactive species prior to
bond formation.67
56

Historically, various methods have been employed using kojic acid derivatives to create
the essential zwitterionic intermediate in situ (Scheme 2.2). Most synthetic strategies leverage
the tautomerization or rearrangement of 3-hydroxy-4-pyrones to oxidopyrylium ylides
(2.12 → 2.13, Path A).67 However, higher temperatures are necessary to initiate the reaction,
which exclude many thermally unstable alkenyl and alkynyl substrates. 68 In addition,
oxidopyrylium cycloadditions performed through group transfer are only effective for
intramolecular processes due to the transience of the active ylide. 67,68
To circumvent the high temperature rearrangement, Wender and co-workers developed
an alternative and milder approach whereby the ylide is created through simple activation of a
methyl triflate-derived oxidopyrylium salt (2.15 → 2.16, Path B).69 The triflate salt or
‘pre-ylide’ is initially synthesized by executing an O-4 alkylation on 3-hydroxy-4-pyrones with
methyl triflate (MeOTf). The resulting salt then engages in low temperature [5 + 2]
cycloadditions when exposed to a non-nucelophilic base or a fluoride source, depending on the
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nature of the R group at O-3. With this method in hand, the Wender group not only demonstrated
intramolecular reactions69a but reported the intermolecular construction of cycloadducts with
both alkenes and alkynes (Scheme 2.3).69b
In our synthetic route to αHTs, we utilize a modified version of the oxidopyrylium
cycloaddition developed by Wender and co-workers.49a A key characteristic of oxidopyrylium
ylides is their capacity to dimerize upon formation (Scheme 2.4A).70 Believing the dimerization
to be detrimental to the overall productivity of the intermolecular oxidopyrylium cycloaddition,
the Wender group optimized against this process by using lower temperatures and a weaker base
(i.e. N,N-dimethylaniline, Scheme 2.3).69b However, the work conducted in our laboratory by
Dr. Christine Meck illustrated that the dimerization is reversible, as a cycloaddition between
dimer 2.24a and dimethyl acetylenedicarboxylate (DMAD) occurs when heated (Scheme
2.4B).49a In addition, our laboratory discovered that ylide 2.23a demethylates in the presence of
N,N-dimethylaniline at higher temperatures, effectively destroying the reaction (Scheme 2.4C).
The demethylation was suppressed with the use of a bulkier base, N,N-diisopropylaniline,
58

permitting an efficient intermolecular oxidopyrylium cycloaddition with a variety of alkynes
(Scheme 2.5 for select examples).
In summary, the harsh demethylation conditions required at the final stage of our αHT
synthesis emerge as a result of the stipulations set by the oxidopyrylium cycloaddition. The O-4
methylation of 3-hydroxy-4-pyrone derivatives to oxidopyrylium triflate salts allows for facile
and effective intra- and intermolecular [5 + 2] cycloadditions versus reaction variants that rely on
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high temperature group transfers and tautomerization. Thus, we shifted our efforts towards
adjusting the cycloaddition phase of Scheme 2.1 in order to remove the methoxy functionality.
2.1.3. Attempts at Synthesizing Alternative Oxidopyrylium Triflate Salts
As detailed earlier, triflate salt 2.2a is very easily generated by methylating allomaltol
(2.18) with MeOTf.49a,69b The process permits a gram-scale synthesis of 2.2a, which is both
storable and bench-stable. In principle, 3-hydroxy-4-pyrones should react with alternative alkyl
triflates to produce novel oxidopyrylium salts. Nevertheless, attempts performed by our
laboratory to synthesize other triflate-derived species, including benzyl and trifluoroethyl triflate
analogs, have been unsuccessful. Therefore, a different strategy is needed to bypass the
formation of α-methoxyenone-containing oxabicycles.
2.2. The Three-Component Oxidopyrylium [5 + 2] Cycloaddition
2.2.1. Serendipitous Discovery and Initial Optimization with Triflate Salt/Base
Due to a serendipitous discovery made by Dr. Christine Meck, our laboratory was able to
develop a procedure to overcome the limitation of exclusively synthesizing α-methoxyenonederived oxabicyclic intermediates.71 Specifically, when ylide 2.23 is treated with various
alcohols prior to the oxidopyrylium cycloaddition, a three-component process transpires,
resulting in the generation of new oxabicyclic products (2.27, Scheme 2.6). The original
observation was made while conducting slower oxidopyrylium cycloaddition reactions with
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Entry

EtOH equiv.

Temperature (ºC)

1
2
3
4
5
6
7
8
9
10
11d

0.33
1
5
5
5
5
5
5
5
5
5

25
25
60c
60c
60c
80c
80c
60

a

Time

a

12 h
1 wk
1h
2h
4h
1h
4h
2h

Yield (2.4f:2.27a)

b

62% (5.2:1)
62% (2.7:1)
65% (1:1.2)
65% (1:1.2)
64% (1:3.9)
63% (1:1.4)
63% (1:2)
63% (1:2.6)
58% (1:1.6)
30% (1:6.2)
56% (1:2.3)

[a] Reaction temperatures and times correspond to the first step. [b] Yields were calculated on the basis
of combined 2.4f and 2.27a, and ratios were determined by 1H NMR integration. [c] Heated with
microwave irradiation. [d] Conventional heating throughout reaction.

ethanol-stabilized chloroform (Table 2.1, Entry 1). Chloroform (CHCl3) with ethanol (EtOH)
stabilizer typically contains 1% alcohol concentration, which corresponds to 0.33 equivalents
under our studied conditions. Following an oxidopyrylium cycloaddition between triflate salt
2.2a and phenylacetylene in the presence of base, approximately 15% of the overall yield is
attributed to the α-ethoxyenone compound 2.27a.
Moving forward with this finding, we ventured to optimize the process towards a higher
output of 2.27a. Our results revealed that an increase in EtOH concentrations led to more
incorporated product, while having no influence on total bicyclic yields (Entries 2-3).
Prolonging the oxidopyrylium cycloaddition did not improve 2.27a production, and resubjecting
bicycle 2.4f to the reaction conditions with EtOH gave no noticeable incorporation. On the other
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hand, when the oxidopyrylium ylide was reacted with alcohol for a period of time prior to alkyne
addition, 2.27a was provided in larger quantities (Entries 4-8). However, upon exposing the
ylide and alcohol to higher temperatures and longer reaction times, observed yields decreased
markedly (Entries 9-10). Lastly, since a multi-hour process in a microwave reactor is
impractical, the three-component cycloaddition was investigated with conventional heating.
Similar yields were obtained between experiments with different heating methods, allowing for
the study of a wider range incorporation times (Entries 7 vs. 11).
After deeming it viable to obtain yields around 50% for 2.27a with a three-component
reaction, we attempted to generate a series of novel oxabicycles by incorporating alternative
alcohols (Table 2.2). During the substrate scope, we found that each alcohol required new
optimization conditions and demonstrated varying levels of efficiency. For example, the more
sterically demanding alcohols, such as isopropanol and neopentanol, produced 2.27m and 2.27k
in lower overall yields and demanded much longer reaction times (Entries 4-9). Alcohols with
even greater steric demand (e.g. t-butanol and trimethylsilanol) displayed no observable
incorporation (not shown). Benzyl and allyl alcohols provided lower yields of 2.27f and 2.27n at
60 ºC for 2 h, demanding shorter intervals and lower temperatures for optimization (Entries 1015). Lastly, attempts at using electron rich substituents, such as p-methoxybenzyl (PMB) alcohol,
failed to supply incorporated species, and instead led to the formation of allomaltol (not shown).
Overall, though reasonably effective for ethanol incorporation, the initial optimization
conditions involving triflate salt 2.2a and base were not very versatile. We speculated that the
reduction in efficiency for other alcohols involved decomposition pathways mediated by the
conjugate acid that forms after deprotonation of 2.2a. Thus, our focus shifted toward conducting
the three-component oxidopyrylium cycloaddition without the use of base.
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Entry

Alcohol (R =)

Temperature (ºC)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Et (2.27a)
Et (2.27a)
Et (2.27a)
i-Pr (2.27m)
i-Pr (2.27m)
i-Pr (2.27m)
Np (2.27k)
Np (2.27k)
Np (2.27k)
Bn (2.27f)
Bn (2.27f)
Bn (2.27f)
Allyl (2.27n)
Allyl (2.27n)
Allyl (2.27n)

60
60
60
60
60
60
60
60
60
60
60
25
60
60
25

a

Time (h)

2
4
12
2
4
12
0.5
2
12
2
0.5
12
2
0.5
12

a

Yield (2.27:2.4f)

b

56% (2.3:1)c
41% (5:1)
13% 2.27a
47% (1:9)
39% (1:3)
10% 2.27m
53% (1:4.4)
51% (1:1.6)
15% (2:1)
15% (3.1)
41% (2:1)
63% (1:1.3)
13% (2:1)
56% (1:1.4)
40% (1:3)

[a] Reaction temperatures and times are for the first step of process prior to addition of alkyne. [b] Yield
calculated from combined isolated 2.4f and 2.27. [c] Average of 2 separate runs.

2.2.2. Mechanistic Hypothesis and Re-Optimization with Oxidopyrylium Dimer
Considering the preliminary results, our proposed mechanistic hypothesis for the alcohol
incorporation involves a nucleophilic aromatic substitution on ylide 2.23 (Scheme 2.7). Though
2.23 rapidly dimerizes to 2.24 and cannot be detected in solution, the transformation is presumed
to be reversible based on previous reports from our laboratory.49a The interconversion ultimately
allows the alcohol to interact with 2.23, generating new ylide species (2.26) that further
undergoes cycloaddition. Alcohol exchange directly with the dimer is improbable due to the
requirement for an SN1-type reaction on a bridgehead carbon and/or the replacement of an
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α-alkoxy group on an enone. Nonetheless, the incorporation mechanism could reasonably entail
an unknown intermediate between the ylide and dimer. Studies are currently being performed in
order obtain a better mechanistic understanding of the three-component reaction.
In order to increase the efficiency of the synthetic method, we leveraged the reversible
dimerization.71 The purified dimer 2.24a was readily prepared in high yields by adding
triethylamine to triflate salt 2.2a, then performing an aqueous ammonium chloride wash. We
surmised that eliminating residual base and stoichiometric conjugate acid emerging from
deprotonation of 2.2a would permit longer incorporation times and limit decomposition. This
assumption was verified as experiments conducted with oxidopyrylium dimer provided greater
overall yields and tolerated prolonged exposure to heating conditions in comparison to the
triflate salt/base combination (Table 2.3). The optimal reaction time for this process was 12
hours, as anything beyond that led to comparable amounts of 2.27b. In addition, lower overall
yields were observed with the 18 and 24 hour time points due to the formation of less 2.4h.
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Yield (%)
Entry

Method

Time (h)b

2.27bc

2.4hd

Total

1
2
3
4
5
6
7
8
9
10

A
B
A
B
A
B
A
B
B
B

2
2
6
6
8
8
12
12
18
24

12
25
25
47
30
47
37
52
51
55

60
56
35
24
28
24
18
24
10
7

72
81
60
71
58
71
55
76
61
62

[a] Equivalents are calculated on the basis of monomeric ylide for consistency. [b] Time for first step, with
conventional heating. [c] Isolated yields following silica gel chromatography. [d] Product 2.4h was isolated
along with benzyl alcohol, and yields were approximated on the basis of the 1H NMR integration ratio of
signature peaks of 2.4h and benzyl alcohol.

With these new reaction conditions in hand, we decided to employ alternative alkynes
and alcohols to the system (Table 2.4). Benzyl-containing oxabicyclic intermediates with a
variety of substituents were generated in 40-65% yield (2.27b-f). Benzyl alcohols with distinct
electronic properties were also used with comparable results (2.27g-h), as electronically poor
benzyl derivatives required less incorporation time. Furthermore, a dimer possessing methylene
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methyl ether groups was implemented without any competitive transetherification (2.27i).
Primary alcohols with adjacent sterics (2.27j-k) or base-sensitive functionality (2.27l) were
successfully incorporated. However, steric limitations apply, with secondary alcohols
necessitating longer reaction times and producing lower yields (2.27m), and tertiary alcohols
showing no product formation. Allyl alcohol again provided diminished yields, which may be
due to competing Claisen-rearrangement-type decomposition pathways (2.27n). In a majority of
cases, an excess amount of alkyne (20 equiv.) was used to maximize product output.
Nonetheless, for more costly reagents, as represented by 1,4-diethynylbenzene, such liberal
usage can be prohibitive. For these situations, decreased quantities of alkyne (10 equiv.) can be
employed with comparable yields (2.27o), and the alkyne can be recovered and recycled (i.e.
80% recovery at a net consumption of 2 equiv.).
In summary, we successfully re-optimized the three-component oxidopyrylium
cycloaddtion by utilizing the purified dimer 2.24a and removing the base from the system. This
protocol granted access to a series of novel α-alkoxyenone-containing oxabicycles through the
incorporation of various alcohols and alkynes, which could not be achieved with the triflate
salt/base combination (Table 2.4). Many of these compounds possess acid- or base-sensitive
protecting groups, such as benzyl and cyanoethyl functionalities respectively, that require much
milder conditions to cleave in comparison to methyl ethers.66 Thus, our next step was to apply
the newly developed synthetic method towards αHT generation.
2.2.3. Utility of Three-Component Reaction in αHT Synthesis
Considering benzyl ethers are widely used in protecting group chemistry and can be
removed more easily than methyl appendages with much weaker acids, 66 our studies began with
bicycle 2.27f. Following a previously reported procedure for benzyl deprotection, 72 we
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discovered that treatment of 2.27f with methane sulfonic acid leads directly to the αHT 2.6a,
despite the presence of benzyl methanesulfonate impurity (Scheme 2.8, Method A). In order to
remove this contaminant, the acid source was changed to a solid-supported sulfonic acid resin,
Amberlyst® 15.73 The obtained yields from the resin reaction were lower, but the product was
much cleaner (Scheme 2.8, Method B). It must be noted that with the latter method, an aqueous
wash is necessary to dissociate the αHT from the resin, most likely due to hydrogen bonding
between the troponoid system and solid-bound sulfonic acids. While the overall mechanism for
the deprotections is unknown, shorter reaction times lead to observable amounts of
benzyloxytropolones along with 2.6a, suggesting that ring opening occurs prior to
debenzylation.71 Overall, these promising results demonstrated that the three-component
oxidopyrylium cycloaddition can be leveraged to synthesize αHTs with much milder conditions
than previously outlined.
2.3. Conclusion
Our group has discovered and developed a new three-component 3-hydroxy-4-pyronebased oxidopyrylium cycloaddition that generates novel oxabicyclic compounds. 71 The data
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presented above illustrates the potential utility of the synthetic method towards αHT assembly, as
a wider range of milder deprotection conditions can be used to bypass harsher demethylation
requirements. The remainder of this thesis will describe further applications of the threecomponent reaction, specifically detailing the solid-phase and fluorous supported synthesis of
αHTs.
2.4. Experimental and Supporting Information
General Information: All starting materials and reagents were purchased from commercially
available sources and used without further purification, with exception of CH2Cl2, which was
purified on a solvent purification system prior to reactions. 63 1H NMR shifts are measured using
the solvent residual peak as the internal standard (CHCl 3 δ 7.26), and reported as follows:
chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet
of doublet, q = quartet, m = multiplet), coupling constant (Hz), integration.
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C NMR shifts are

measured using the solvent residual peak as the internal standard (CDCl3 δ 77.16), and reported
as chemical shifts. Infrared (IR) spectral bands are characterized as broad (br), strong (s),
medium (m), and weak (w). Mass spectra were recorded on a spectrometer by electrospray
ionization (ESI) technique and time-of-flight (TOF) mass analyzer. Microwave reactions were
performed via the Biotage® Intiator (External IR Temperature Sensor). Where noted, reaction
products were purified via silica gel chromatography using a Biotage ® Isolera Prime, with
Biotage® SNAP 10 g cartridges, in a solvent system of ethyl acetate (EtOAc) in hexane.
Synthesis of Oxidopyrylium Dimers:
(1R,2S,6S,7R)-6,9-Dimethoxy-4,7-dimethyl-3,11-dioxatricyclo[5.3.1.12,6]dodeca-4,8-diene10,12-dione (2.24a). To a solution of triflate salt 2.2a (5 g, 17.2 mmol) in CH2Cl2 (43 ml) was
added triethylamine (2.89 mL, 20.7 mmol, 1.2 equiv.). After it was stirred for 10 min at room
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temperature, the reaction mixture was washed with aqueous NH4Cl (5 x 50 mL). The organic
layer was dried with Na2SO4, filtered, and concentrated under reduced pressure to yield 2.24a as
a pale yellow solid (2.21 g, 92% yield), demonstrating 1H NMR data consistent with previously
reported data.49a 1H NMR (400 MHz, CDCl3): δ 5.89 (s, 1H), 4.74 (d, J = 2.7 Hz, 1H), 4.69
(s, 1H), 4.42 (d, J = 2.7 Hz, 1H), 3.59 (s, 3H), 3.40 (s, 3H), 1.95 (s, 3H), 1.42 (s, 3H).
(1R,2S,6S,7S)-6,9-Dimethoxy-4,7-bis(methoxymethyl)-3,11-dioxatricyclo[5.3.1.12,6]dodeca4,8-diene-10,12-dione (2.24b). To a solution of 5-hydroxy-4-methoxy-2-(methoxymethyl)pyrylium trifluoromethanesulfonate (1.64 g, 5.12 mmol) in CH2Cl2 (13 ml) was added
triethylamine (857 μL, 6.15 mmol, 1.2 equiv.). After it was stirred for 10 min at room
temperature, the reaction mixture was washed with aqueous NH4Cl (5 x 20 mL). The organic
layer was dried with Na2SO4, filtered, and concentrated under reduced pressure to yield 2.24b as
a brown solid (683.4 mg, 78% yield). Melting Point (MP) = 140-143 ºC. Rf = 0.25 in 50%
EtOAc in hexanes. IR (thin film, KBr): 3074 (w), 2938 (m), 2839 (m), 1748 (s) 1705 (s), 1669
(m), 1621 (s), 1455 (m), 1369 (m), 1282 (m), 1194 (s), 1105 (s), 992 (m), 901 (m), 834 (m), 729
(m) cm-1. 1H NMR (400 MHz, CDCl3): δ 6.00 (s, 1H), 5.00 (s, 1H), 4.91 (d, J = 2.7 Hz, 1H),
4.54 (d, J = 2.7 Hz, 1H), 4.03 (d, J = 13.5 Hz, 1H), 3.96 (d, J = 13.6 Hz, 1H), 3.88
(d, J = 10.4 Hz, 1H), 3.67 (d, J = 11.1 Hz, 1H), 3.66 (s, 3H), 3.47 (s, 3H), 3.43 (s, 3H), 3.43
(s, 3H).

13

C NMR (100 MHz, CDCl3): δ 197.4, 185.1, 157.2, 151.2, 115.7, 95.7, 87.3, 86.6,

85.2, 82.1, 73.5, 70.6, 59.9, 58.7, 55.4, 54.4. HRMS (ESI+): m/z calc’d for C16H21O8+:
341.1231. Found: 341.1233.
Procedure for Alcohol Incorporation/Cycloaddition Sequence:
3-Ethoxy-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27a). Representative
Procedure for Synthesis of 2.27a. Triflate salt 2.2a (50 mg, 0.172 mmol), N,N-diisopropyl
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aniline (41 μL, 0.208 mmol, 1.2 equiv.), and CDCl3 (0.5 M, 344 μL) were placed in a sealed tube
reactor (Biotage® microwave reaction vial, 0.5-2 mL) and stirred until no solid was observed.
Ethanol (50 μL, 0.860 mmol, 5 equiv.) was then added, and the reaction mixture was heated to
60 ºC in silicone oil bath for 2 h. After the reaction mixture was cooled to room temperature,
phenyl acetylene (378 µL, 3.44 mmol, 20 equiv.) was added and the sealed tube was heated to
100 ºC for 30 min. The reaction mixture was then immediately purified by column
chromatography (silica gel, 6 in. height of silica gel, 18 cm x 1.8 cm, solvent gradient: hexanes
(50 mL); 5% EtOAc in hexanes (100 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in
hexanes (150 mL)). Product fractions were concentrated to give 2.27a as a yellowish oil (17 mg,
38% yield) and 2.4f as a yellow solid (8 mg, 19% yield). The 1H NMR for 2.4f was consistent
with previously reported data.49a Characterization Data for 2.27a. Rf = 0.21 in 15% EtOAc in
hexanes. IR (thin film, KBr): 3057 (w), 2981 (m), 2936 (w), 1713 (s), 1603 (s), 1493 (m), 1446
(m), 1381 (w), 1339 (m), 1264 (m), 1130 (s), 1058 (m), 898 (m), 864 (m), 755 (s), 697 (m) cm -1.
1

H NMR (400 MHz, CDCl3): δ 7.41 – 7.30 (m, 3H), 7.30 – 7.25 (m, 2H), 6.27 (d, J = 2.5 Hz,

1H), 6.18 (s, 1H), 4.98 (d, J = 2.5 Hz, 1H), 3.85 – 3.67 (m, 2H), 1.66 (s, 3H), 1.36 (t, J = 7.0 Hz,
3H).

13

C NMR (50 MHz, CDCl3): δ 190.2, 158.8, 145.2, 133.2, 128.82, 128.77, 126.1, 123.2,

119.7, 86.5, 86.0, 63.3, 22.2, 14.3. HRMS (ESI+): m/z calc’d for C16H17O3+: 257.1172. Found:
257.1173.
tert-Butyl 3-(benzyloxy)-5-methyl-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6-carboxylate
(2.27b). Representative Procedure Employing Method A. Triflate salt 1 (50 mg, 0.172 mmol),
N,N-diisopropyl aniline (41 μL, 0.208 mmol, 1.2 equiv.), and CH2Cl2 (0.5 M, 344 μL) were
placed in a sealed tube reactor (Biotage ® microwave reaction vial, 0.5-2 mL) and stirred until no
solid was observed. Benzyl alcohol (89 μL, 0.860 mmol, 5 equiv.) was then added, and the
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reaction mixture was heated to 60 ºC in silicone oil bath for 12 h. After the reaction mixture was
cooled to room temperature, tert-butyl propiolate (472 µL, 3.44 mmol, 20 equiv.) was added to
the sealed tube, and the reaction mixture was subjected to microwave irradiation at 100 ºC for
15 min. The reaction mixture was then immediately purified by column chromatography (silica
(10 g), 0% EtOAc/hexane to 10% EtOAc/hexane gradient over 30 column volumes), yielding
2.27b as a white solid (21.6 mg, 37% yield) and 2.4h as a white solid (8.3 mg, 18%).
Representative Procedure Employing Method B. Dimer 2.24a (24 mg, 0.0860 mmol), benzyl
alcohol (89 μL, 0.860 mmol, 10 equiv.), and CH2Cl2 (0.25 M, 344 μL) were placed in a sealed
tube reactor (Biotage® microwave reaction vial, 0.5-2 mL), and the reaction mixture was heated
to 60 ºC in silicone oil bath for 12 h. tert-Butyl propiolate (472 µL, 3.44 mmol, 40 equiv.) was
added to the sealed tube, and the reaction mixture was subjected to microwave irradiation at
100 ºC for 15 min. The reaction mixture was then immediately purified by column
chromatography (silica (10 g), 0% EtOAc/hexane to 10% EtOAc/hexane gradient over
25 column volumes), yielding 2.27b as a white solid (30.8 mg, 52% yield) and 2.4h as a white
solid (10.8 mg, 24%). Characterization Data for 2.27b. MP = 99-102 ºC. Rf = 0.22 in 10%
EtOAc in hexanes. IR (thin film, KBr): 3065 (w), 3034 (w), 2978 (w), 2936 (w), 1706 (s), 1614
(m), 1602 (m), 1455 (m), 1369 (m), 1327 (s), 1160 (s), 1122 (s), 1072 (s), 874 (m), 751 (m), 698
(m) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.38–7.27 (m, 5H), 6.98 (d, J = 2.5 Hz, 1H), 6.13
(s, 1H), 4.99 (d, J = 2.5 Hz, 1H), 4.80 (d, J = 11.9 Hz, 1H), 4.73 (d, J = 11.9 Hz, 1H), 1.72
(s, 3H), 1.48 (s, 9H). 13C NMR (100 MHz, CDCl3): δ 189.0, 162.2, 151.1, 144.0, 137.8, 135.6,
128.7, 128.3, 127.6, 121.6, 86.0, 85.5, 82.3, 69.6, 28.2, 21.5. HRMS (ESI+): m/z calc’d for
C20H23O5+: 343.1540. Found: 343.1545. Characterization Data for 2.4h. MP = 82-85 ºC.
Rf = 0.26 in 15% EtOAc in hexanes. IR (thin film, KBr): 3092 (w), 2979 (w), 2937 (w), 1708
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(s), 1615 (m), 1605 (m), 1456 (w), 1369 (m), 1328 (m), 1272 (m), 1161 (m), 1128 (m), 1073 (m),
1024 (m), 873 (w), 760 (w) cm-1. 1H NMR (400 MHz, CDCl3): δ 6.96 (d, J = 2.5 Hz, 1H), 6.06
(s, 1H), 4.97 (d, J = 2.5 Hz, 1H), 3.55 (s, 3H), 1.74 (s, 3H), 1.50 (s, 9H).

13

C NMR (50 MHz,

CDCl3): δ 189.2, 162.3, 151.1, 145.1, 137.6, 119.7, 85.8, 85.6, 82.4, 54.8, 28.3, 21.5. HRMS
(ESI+): m/z calc’d for C14H19O5+: 267.1227. Found: 267.1229.
Ethyl 3-(benzyloxy)-5-methyl-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6-carboxylate (2.27c).
Dimer 2.24a (24 mg, 0.0860 mmol), benzyl alcohol (89 μL, 0.860 mmol, 10 equiv.), and CH2Cl2
(0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage® microwave reaction vial,
0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicone oil bath for 12 h. Ethyl
propiolate (349 µL, 3.44 mmol, 40 equiv.) was added to the sealed tube, and the reaction mixture
was subjected to microwave irradiation at 100 ºC for 15 min. The reaction mixture was then
immediately purified by column chromatography (silica (10 g), 0% EtOAc/hexane to 15%
EtOAc/hexane gradient over 33 column volumes), giving 2.27c as a yellow oil (29.6 mg, 55%)
and 2.4d as a yellow oil (4 mg, 10% yield). The 1H NMR for 2.4d was consistent with previously
reported data.49a Characterization Data for 2.27c. Rf = 0.25 in 15% EtOAc in hexanes. IR (thin
film, KBr): 3065 (w), 2982 (w), 2937 (w), 1711 (s), 1615 (m), 1602 (m), 1455 (m), 1370 (m),
1317 (s), 1221 (m), 1123 (s), 1073 (s), 1037 (m), 875 (m), 750 (m), 698 (m) cm -1. 1H NMR
(400 MHz, CDCl3): δ 7.37 – 7.27 (m, 5H), 7.09 (d, J = 2.5 Hz, 1H), 6.16 (s, 1H), 5.03
(d, J = 2.5 Hz, 1H), 4.77 (d, J = 11.7 Hz, 1H), 4.72 (d, J = 11.7 Hz, 1H), 4.30 – 4.17 (m, 2H),
1.75 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H).

13

C NMR (100 MHz, CDCl3): δ 188.7, 162.9, 149.6,

144.1, 138.8, 135.4, 128.7, 128.3, 127.7, 121.4, 86.2, 85.6, 69.7, 61.3, 21.4, 14.3. HRMS
(ESI+): m/z calc’d for C18H19O5+: 315.1227. Found: 315.1228.
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6-Acetyl-3-(benzyloxy)-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27d). Dimer
2.24a (24 mg, 0.0860 mmol), benzyl alcohol (89 μL, 0.860 mmol, 10 equiv.), and CH2Cl2
(0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage ® microwave reaction vial,
0.5-2 mL), and the reaction was heated to 60 ºC in silicone oil bath for 12 h. 3-Butyne-2-one
(269 µL, 3.44 mmol, 40 equiv.) was added to the sealed tube, and the reaction mixture was
subjected to microwave irradiation at 100 ºC for 15 min. The reaction mixture was then
immediately purified by column chromatography (silica (10 g), 0% EtOAc/hexane to 25%
EtOAc/hexane gradient over 60 column volumes), giving 2.27d as a pale yellow solid (32 mg,
65% yield) and 2.4e as a yellow solid (5.8 mg, 16%). The 1H NMR for 2.4e was consistent with
previously reported data.49a Characterization Data for 2.27d. MP = 84-87 ºC. Rf = 0.32 in 25%
EtOAc in hexanes. IR (thin film, KBr): 3066 (w), 3034 (w), 2981 (w), 2936 (w), 1712 (s), 1672
(s), 1608 (s), 1455 (m), 1365 (m), 1311 (s), 1269 (m), 1121 (s), 1065 (m), 872 (s), 739 (m), 699
(m) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.37 – 7.26 (m, 5H), 7.04 (d, J = 2.5 Hz, 1H), 6.18
(s, 1H), 5.06 (d, J = 2.6 Hz, 1H), 4.73 (d, J = 11.6 Hz, 1H), 4.69 (d, J = 11.6 Hz, 1H), 2.36
(s, 3H), 1.71 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 194.3, 188.7, 156.4, 144.1, 139.1, 135.4,
128.7, 128.4, 127.8, 121.5, 86.1, 86.0, 69.7, 27.8, 21.3. HRMS (ESI+): m/z calc’d for
C17H17O4+: 285.1121. Found: 285.1122.
Dimethyl 3-(benzyloxy)-1-methyl-4-oxo-8-oxabicyclo[3.2.1]octa-2,6-diene-6,7-dicarboxylate
(2.27e). Dimer 2.24a (24 mg, 0.0860 mmol), benzyl alcohol (89 μL, 0.860 mmol, 10 equiv.), and
CH2Cl2 (0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage ® microwave reaction
vial, 0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicone oil bath for 12 h.
Dimethyl acetylenedicarboxylate (422 µL, 3.44 mmol, 40 equiv.) was added to the sealed tube,
and the reaction mixture was subjected to microwave irradiation at 100 ºC for 10 min. The
reaction mixture was then immediately purified by column chromatography (silica (10 g), 0%
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EtOAc/hexane to 35% EtOAc/hexane gradient over 45 column volumes), giving 2.27e as a pale
yellow solid (29.8 mg, 48% yield) and 2.4a as a yellow solid (5.2 mg, 11%). The 1H NMR for
2.4a was consistent with previously reported data. 49a Characterization Data for 2.27e.
MP = 104-107 ºC. Rf = 0.26 in 25% EtOAc in hexanes. IR (thin film, KBr): 3066 (w), 3034
(w), 2954 (w), 1721 (s), 1652 (w), 1605 (m), 1455 (w), 1437 (m), 1323 (m), 1287 (s), 1124 (m),
1073 (m), 1031 (m), 868 (w), 747 (m), 698 (w)

cm-1. 1H NMR (400 MHz, CDCl3): δ

7.39 – 7.28 (m, 5H), 6.09 (s, 1H), 5.26 (s, 1H), 4.78 (s, 2H), 3.87 (s, 3H), 3.79 (s, 3H), 1.64
(s, 3H). 13C NMR (100 MHz, CDCl3): δ 186.8, 163.8, 161.5, 153.5, 144.3, 136.0, 135.2, 128.7,
128.4, 127.8, 119.9, 87.9, 86.8, 69.9, 52.9, 52.8, 20.9. HRMS (ESI+): m/z calc’d for C19H19O7+:
359.1125. Found: 359.1130.
3-(Benzyloxy)-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27f). Dimer
2.24a (24 mg, 0.0860 mmol), benzyl alcohol (89 μL, 0.860 mmol, 10 equiv.), and CH2Cl2
(0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage ® microwave reaction vial,
0.5-2 mL), and the reaction was heated to 60 ºC in silicone oil bath for 12 h. Phenyl acetylene
(378 µL, 3.44 mmol, 40 equiv.) was added to the sealed tube, and the reaction mixture was
subjected to microwave irradiation at 100 ºC for 30 min. The reaction mixture was then
immediately purified by column chromatography (silica gel, 6 inch height of silica gel, 18 cm x
1.8 cm, solvent gradient: hexanes (50 mL); 2% EtOAc in hexanes (100 mL); 5% EtOAc in
hexanes (100 mL); 7% EtOAc in hexanes (200 mL); 10% EtOAc in hexanes (100 mL)). Product
fractions concentrated to give 2.27f as a white solid (21.9 mg, 40% yield). MP = 112-114 ºC.
Rf = 0.24 in 15% EtOAc in hexanes. IR (thin film, KBr): 3061 (w), 3033 (w), 2979 (w), 2933
(w), 1709 (s), 1604 (s), 1491 (m), 1454 (m), 1339 (m), 1263 (m), 1125 (s), 1106 (m), 1058 (m),
866 (m), 754 (s), 697 (s) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.40 – 7.27 (m, 8H), 7.18 – 7.12

75

(m, 2H), 6.27 (d, J = 2.4 Hz, 1H), 6.24 (s, 1H), 5.01 (d, J = 2.5 Hz, 1H), 4.92 (d, J = 12.0 Hz,
1H), 4.79 (d, J = 12.0 Hz, 1H), 1.62 (s, 3H). 13C NMR (50 MHz, CDCl3): δ 189.9, 158.9, 144.7,
135.6, 133.1, 128.8, 128.7, 128.3, 127.5, 126.0, 123.2, 121.6, 86.5, 86.1, 69.7, 22.0. HRMS
(ESI+): m/z calc’d for C21H19O3+: 319.1329. Found: 319.1332.
5-Methyl-3-((4-methylbenzyl)oxy)-6-(4-(trifluoromethyl)phenyl)-8-oxabicyclo[3.2.1]octa3,6-dien-2-one (2.27g). Dimer 2.24a (25 mg, 0.0892 mmol), 4-methylbenzyl alcohol (105 mg,
0.860 mmol, 9.6 equiv.), and CH2Cl2 (0.26 M, 344 μL) were placed in a sealed tube reactor
(Biotage® microwave reaction vial, 0.5-2 mL), and the reaction mixture was heated to 60 ºC in
silicone oil bath for 12 h. 4-Ethynyl-α,α,α-trifluorotoluene (561 µL, 3.44 mmol, 39 equiv.) was
added to the sealed tube, and the reaction mixture was subjected to microwave irradiation at
100 ºC for 35 min. The reaction was then immediately purified by column chromatography
(silica (10 g), 0% EtOAc/hexane to 15% EtOAc/hexane gradient over 25 column volumes),
giving 2.27g as a yellow solid (30.2 mg, 42% yield). MP = 115-119 ºC. Rf = 0.31 in 15% EtOAc
in hexanes. IR (thin film, KBr): 3054 (w), 2982 (w), 2936 (w), 1712 (m), 1615 (m), 1603 (m),
1455 (w), 1326 (s), 1165 (m), 1125 (s), 1069 (s), 1016 (w), 869 (m), 835 (w), 804 (w), 740 (w)
cm-1. 1H NMR (400 MHz, CDCl3): δ 7.57 (d, J = 8.1 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 7.19
(d, J = 8.0 Hz, 2H), 7.13 (d, J = 7.9 Hz, 2H), 6.36 (d, J = 2.4 Hz, 1H), 6.18 (s, 1H), 5.02
(d, J = 2.5 Hz, 1H), 4.93 (d, J = 12.1 Hz, 1H), 4.76 (d, J = 12.1 Hz, 1H), 2.32 (s, 3H), 1.59
(s, 3H).

13

C NMR (100 MHz, CDCl3): δ 189.6 (s), 157.8 (s), 144.5 (s), 138.1 (s), 136.8

(d, J = 1.2 Hz), 132.5 (s), 130.6 (q, J = 32.7 Hz), 129.5 (s), 127.5 (s), 126.3 (s), 125.7
(q, J = 3.8 Hz), 125.6 (s), 124.0 (q, J = 272.1 Hz), 121.4 (s), 86.5 (s), 86.3 (s), 69.7 (s), 21.9 (s),
21.2 (s). HRMS (ESI+): m/z calc’d for C23H19 F3O3Na+: 423.1179. Found: 423.1182.
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6-(4-Methoxyphenyl)-5-methyl-3-((4-(trifluoromethyl)benzyl)oxy)-8-oxabicyclo[3.2.1]octa3,6-dien-2-one (2.27h). Dimer 2.24a (25 mg, 0.0892 mmol), 4-(trifluoromethyl)benzyl alcohol
(118 μL, 0.860 mmol, 9.6 equiv.), and CH2Cl2 (0.26 M, 344 μL) were placed in a sealed tube
reactor (Biotage® microwave reaction vial, 0.5-2 mL), and the reaction mixture was heated to
60 ºC in silicone oil bath for 4 h. 4-Ethynylanisole (446 µL, 3.44 mmol, 39 equiv.) was added to
the sealed tube, and the reaction mixture was subjected to microwave irradiation at 100 ºC for
40 min. The reaction was then immediately purified by column chromatography (silica (10 g),
0% EtOAc/hexane to 20% EtOAc/hexane gradient over 30 column volumes), giving product
contaminated with aryl alcohol. The aryl alcohol was removed with vacuum distillation, giving
2.27h as a yellow oil (34.1 mg, 46% yield). Rf = 0.23 in 20% EtOAc in hexanes. IR (thin film,
KBr): 3055 (w), 2977 (w), 2937 (w), 1711 (s), 1607 (m), 1510 (s), 1457 (w), 1326 (s), 1253 (s),
1164 (m), 1125 (s), 1067 (s), 1020 (m), 867 (m), 828 (m), 725 (w) cm -1. 1H NMR (400 MHz,
CDCl3): δ 7.60 (d, J = 8.0 Hz, 2H), 7.45 (d, J = 7.9 Hz, 2H), 7.08 (d, J = 8.6 Hz, 2H), 6.86
(d, J = 8.6 Hz, 2H), 6.19 (s, 1H), 6.16 (d, J = 1.8 Hz, 1H), 4.99 (d, J = 2.1 Hz, 1H), 4.97
(d, J = 13.5 Hz, 1H), 4.83 (d, J = 12.7 Hz, 1H), 3.82 (s, 3H), 1.62 (s, 3H). 13C NMR (100 MHz,
CDCl3): δ 189.7 (s), 160.2 (s), 158.5 (s), 144.5 (s), 139.8 (q, J = 1.1 Hz), 130.5 (q, J = 32.5 Hz),
127.5 (s), 127.3 (s), 125.8 (q, J = 3.7 Hz), 125.4 (s), 124.1 (q, J = 272.1 Hz), 122.1 (s), 121.0 (s),
114.3 (s), 86.4 (s), 86.0 (s), 68.8 (s), 55.5 (s), 22.1 (s). HRMS (ESI+): m/z calc’d for
C23H20 F3O4+: 417.1308. Found: 417.1310.
Ethyl 3-(benzyloxy)-5-(methoxymethyl)-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6carboxylate (2.27i). Dimer 2.24b (29 mg, 0.0860 mmol), benzyl alcohol (89 μL, 0.860 mmol,
10 equiv.), and CH2Cl2 (0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage ®
microwave reaction vial, 0.5-2 mL), and the reaction was heated to 60 ºC in silicone oil bath for
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12 h. Ethyl propiolate (349 µL, 3.44 mmol, 40 equiv.) was added to the sealed tube, and the
reaction mixture was subjected to microwave irradiation at 100 ºC for 20 min. The reaction
mixture was then immediately purified by column chromatography (silica (10 g), 0%
EtOAc/hexane to 30% EtOAc/hexane gradient over 35 column volumes), yielding 2.27i as a
white solid (31.8 mg, 54% yield) and 2.4i as a yellow oil (9 mg, 20%). Characterization Data for
2.27i. MP = 80-84 ºC. Rf = 0.30 in 30% EtOAc in hexanes. IR (thin film, KBr): 3065 (w), 2983
(w), 2931 (w), 1712 (s), 1617 (w), 1604 (m), 1455 (w), 1370 (w), 1320 (m), 1278 (w), 1217 (m),
1114 (m), 1097 (m), 1032 (w), 869 (w), 749 (w) cm-1. 1H NMR (400 MHz, CDCl3): δ
7.37 – 7.27 (m, 5H), 7.12 (d, J = 2.4 Hz, 1H), 6.09 (s, 1H), 5.12 (d, J = 2.4 Hz, 1H), 4.78
(d, J = 11.6 Hz, 1H), 4.73 (d, J = 11.6 Hz, 1H), 4.30 – 4.18 (m, 2H), 3.97 (d, J = 10.9 Hz, 1H),
3.93 (d, J = 11.0 Hz 1H), 3.44 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ
188.4, 162.7, 147.5, 145.2, 139.0, 135.3, 128.7, 128.4, 127.8, 116.8, 88.4, 86.4, 72.2, 69.8, 61.4,
59.8, 14.3. HRMS (ESI+): m/z calc’d for C19H21O6+: 345.1333. Found: 345.1334.
Characterization Data for 2.4i. Rf = 0.27 in 35% EtOAc in hexanes. IR (thin film, KBr): 3067
(w), 2982 (w), 2935 (w), 1712 (s), 1618 (m), 1607 (m), 1455 (w), 1319 (m), 1218 (m), 1120 (s),
1098 (s), 1033 (m), 986 (w), 868 (w), 828 (w), 769 (w) cm-1. 1H NMR (400 MHz, CDCl3): δ
7.11 (d, J = 2.5 Hz, 1H), 6.01 (s, 1H), 5.10 (d, J = 2.5 Hz, 1H), 4.25 (q, J = 7.0 Hz, 2H), 4.00
(d, J = 10.9 Hz, 1H), 3.97 (d, J = 10.8 Hz, 1H), 3.57 (s, 3H), 3.45 (s, 3H), 1.32 (t, J = 7.1 Hz,
3H). 13C NMR (100 MHz, CDCl3): δ 188.7, 162.8, 147.7, 146.3, 138.9, 115.0, 88.4, 86.2, 72.3,
61.4, 59.9, 54.9, 14.3. HRMS (ESI+): m/z calc’d for C13H17O6+: 269.1020. Found: 269.1024.
Ethyl 5-methyl-3-(neopentyloxy)-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6-carboxylate
(2.27j). Dimer 2.24a (25 mg, 0.0892 mmol), neopentyl alcohol (76 mg, 0.860 mmol, 9.6 equiv.),
and CDCl3 (0.26 M, 344 μL) were placed in a sealed tube reactor (Biotage ® microwave reaction
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vial, 0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicone oil bath for 12 h. Ethyl
propiolate (349 µL, 3.44 mmol, 39 equiv.) was added to the sealed tube, and the reaction mixture
was subjected to microwave irradiation at 100 ºC for 20 min. The reaction mixture was then
immediately purified by column chromatography (silica (10 g), 0% EtOAc/hexane to 25%
EtOAc/hexane gradient over 25 column volumes), giving 2.27j as a yellow solid (29.8 mg, 57%
yield) and 2.4d as a yellow solid (10.9 mg, 26% yield). The 1H NMR for 2.4d was consistent
with previously reported data.49a Characterization Data for 2.27j. MP = 69-73 °C. Rf = 0.31 in
10% EtOAc in hexanes. IR (thin film, KBr): 3066 (w), 2958 (m), 2870 (w), 1712 (s), 1616 (m),
1602 (m), 1478 (w), 1367 (m), 1316 (s), 1220 (m), 1125 (s), 1074 (s), 994 (w), 874 (m), 752 (m),
677 (w) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.09 (d, J = 2.5 Hz, 1H), 6.02 (s, 1H), 4.99
(d, J = 2.5 Hz, 1H), 4.24 (q, J = 6.9 Hz, 2H), 3.26 (d, J = 8.9 Hz, 1H), 3.21 (d, J = 8.9 Hz, 1H),
1.75 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H), 0.96 (s, 9H).

13

C NMR (100 MHz, CDCl3): δ 188.7,

163.1, 149.6, 144.8, 138.9, 119.7, 86.2, 85.6, 77.2, 61.2, 31.8, 26.7, 21.5, 14.3. HRMS (ESI+):
m/z calc’d for C16H23O5+: 295.1540. Found: 295.1542.
5-Methyl-3-(neopentyloxy)-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27k). Dimer
2.24a (25 mg, 0.0892 mmol), neopentyl alcohol (76 mg, 0.860 mmol, 9.6 equiv.), and CDCl 3
(0.26 M, 344 μL) were placed in a sealed tube reactor (Biotage ® microwave reaction vial,
0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicone oil bath for 12 h. Phenyl
acetylene (378 µL, 3.44 mmol, 39 equiv.) was added to the sealed tube, and the reaction mixture
was subjected to microwave irradiation at 100 ºC for 1 h. The reaction was then immediately
purified by column chromatography (silica gel, 6 inch height of silica gel, 18 cm x 1.8 cm,
solvent gradient: hexanes (50 mL); 2% EtOAc in hexanes (100 mL); 3% EtOAc in hexanes
(100 mL); 10% EtOAc in hexanes (100 mL); 15% EtOAc in hexanes (100 mL)). Product
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fractions were concentrated to give 2.27k as a yellow solid (22.9 mg, 43% yield) and 2.4f as a
yellow solid (3.2 mg, 7% yield). The 1H NMR for 2.4f was consistent with previously reported
data.49a Characterization Data for 2.27k. MP = 114-117 °C. Rf = 0.33 in 10% EtOAc in hexanes.
IR (thin film, KBr): 3057 (w), 2957 (m), 2869 (w), 1714 (s), 1603 (m), 1478 (w), 1446 (w),
1365 (w), 1338 (w), 1260 (w), 1130 (m), 1059 (w), 995 (w), 865 (m), 755 (m), 697 (w) cm -1.
1

H NMR (400 MHz, CDCl3): δ 7.42 – 7.27 (m, 5H), 6.29 (d, J = 2.4 Hz, 1H), 6.14 (s, 1H), 4.97

(d, J = 2.5 Hz, 1H), 3.34 (d, J = 8.8 Hz, 1H), 3.25 (d, J = 8.8 Hz, 1H), 1.67 (s, 3H), 0.99 (s, 9H).
13

C NMR (100 MHz, CDCl3): δ 189.7, 158.7, 145.7, 133.3, 128.8, 128.7, 126.1, 123.3, 119.4,

86.5, 86.1, 77.3, 31.8, 26.7, 22.2. HRMS (ESI+): m/z calc’d for C19H23O3+: 299.1642. Found:
299.1645.
3-((1-Methyl-4-oxo-7-phenyl-8-oxabicyclo[3.2.1]octa-2,6-dien-3-yl)oxy)propanenitrile
(2.27l). Dimer 2.24a (25 mg, 0.0892 mmol), 3-hydroxypropionitrile (59 μL, 0.860 mmol,
9.6 equiv.), and CDCl3 (0.26 M, 344 μL) were placed in a sealed tube reactor (Biotage ®
microwave reaction vial, 0.5-2 mL), and the reaction was heated to 60 ºC in silicone oil bath for
12 h. Phenyl acetylene (378 µL, 3.44 mmol, 39 equiv.) was added to the sealed tube, and the
reaction mixture was subjected to microwave irradiation at 100 ºC for 35 min. The reaction
mixture was then immediately purified by column chromatography (silica (10 g), 0%
EtOAc/hexane to 40% EtOAc/hexane gradient over 30 column volumes), giving 2.27l as an
orange oil (21.1 mg, 42% yield) and 2.4f as a yellow solid (9.6 mg, 22%). The 1H NMR for 2.4f
was consistent with previously reported data. 49a Characterization Data for 2.27l. Rf = 0.24 in
35% EtOAc in hexanes. IR (thin film, KBr): 3058 (w), 2979 (w), 2937 (w), 2253 (w), 1710 (s),
1606 (m), 1492 (w), 1446 (w), 1342 (w), 1264 (w), 1132 (s), 1057 (m), 878 (m), 864 (m), 755
(m), 698 (m) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.43 – 7.33 (m, 3H), 7.30 – 7.23 (m, 2H),
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6.32 (s, 1H), 6.29 (d, J = 2.4 Hz, 1H), 5.00 (d, J = 2.5 Hz, 1H), 4.05 – 3.87 (m, 2H), 2.81
(t, J = 6.8 Hz, 2H), 1.68 (s, 3H).

13

C NMR (100 MHz, CDCl3): δ 189.2, 158.5, 144.3, 132.9,

129.0, 128.9, 126.1, 123.2, 122.7, 116.7, 86.4, 86.0, 62.7, 22.0, 18.2. HRMS (ESI+): m/z calc’d
for C17H15NO3Na+: 304.0944. Found: 304.0948.
3-Isopropoxy-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27m). Dimer
2.24a (25 mg, 0.0892 mmol), isopropyl alcohol (66 μL, 0.860 mmol, 9.6 equiv.), and CDCl3
(0.26 M, 344 μL) were placed in a sealed tube reactor (Biotage ® microwave reaction vial,
0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicone oil bath for 36 h. Phenyl
acetylene (378 µL, 3.44 mmol, 39 equiv.) was added to the sealed tube, and the reaction mixture
was subjected to microwave irradiation at 100 ºC for 1 h. The reaction mixture was then
immediately purified by column chromatography (silica gel, 6 inch height of silica gel, 18 cm x
1.8 cm, solvent gradient: hexanes (50 mL); 5% EtOAc in hexanes (100 mL); 8% EtOAc in
hexanes (100 mL); 10% EtOAc in hexanes (100 mL), 15% EtOAc in hexanes (100 mL)).
Product fractions were concentrated to give 2.27m as a yellowish oil (15.3 mg, 32% yield) and
2.4f as a yellowish solid (11.3 mg, 26% yield). The 1H NMR for 2.4f was consistent with
previously reported data.49a Characterization Data for 2.27m. Rf = 0.27 in 15% EtOAc in
hexanes. IR (thin film, KBr): 3057 (w), 2979 (m), 2935 (w) 1710 (s), 1600 (s), 1596 (s), 1493
(w), 1447 (w), 1384 (w), 1375 (w), 1263 (w), 1125 (s), 1058 (w), 865 (m), 754 (m), 697 (w)
cm-1. 1H NMR (400 MHz, CDCl3): δ 7.42 – 7.31 (m, 3H), 7.30 – 7.25 (m, 2H), 6.28
(d, J = 2.4 Hz, 1H), 6.19 (s, 1H), 4.98 (d, J = 2.5 Hz, 1H), 4.24 (sept, J = 6.1 Hz, 1H), 1.66
(s, 3H), 1.32

(d, J = 6.1 Hz, 3H), 1.25 (d, J = 6.0 Hz, 3H).
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C NMR (50 MHz, CDCl3): δ

190.7, 158.8, 143.8, 133.3, 128.9, 128.7, 126.1, 123.4, 121.1, 86.5, 86.1, 69.9, 22.2, 21.5. HRMS
(ESI+): m/z calc’d for C17H19O3+: 271.1329. Found: 271.1331.
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3-(Allyloxy)-5-methyl-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27n). Dimer 2.24a
(25 mg, 0.0892 mmol), allyl alcohol (58 μL, 0.860 mmol, 9.6 equiv.), and CDCl 3 (0.26 M,
344 μL) were placed in a sealed tube reactor (Biotage ® microwave reaction vial, 0.5-2 mL), and
the reaction mixture was heated to 60 ºC in silicone oil bath for 12 h. Phenyl acetylene (378 µL,
3.44 mmol, 39 equiv.) was added to the sealed tube, and the reaction mixture was subjected to
microwave irradiation at 100 ºC for 30 min. The reaction mixture was then immediately purified
by column chromatography (silica gel, 6 inch height of silica gel, 18 cm x 1.8 cm, solvent
gradient: hexanes (50 mL); 2% EtOAc in hexanes (100 mL); 5% EtOAc in hexanes (100 mL);
7% EtOAc in hexanes (150 mL); 10% EtOAc in hexanes (50 mL); 15% EtOAc in hexanes
(100 mL)). Product fractions were concentrated to give 2.27n as yellowish oil (11.5 mg, 24%
yield) and 2.4f as yellowish solid (5.2 mg, 12% yield). The 1H NMR for 2.4f was consistent with
previously reported data.49a Characterization Data for 2.27n. Rf = 0.24 in 15% EtOAc in
hexanes. IR (thin film, KBr): 3081 (w), 3057 (w), 2981 (w), 2935 (w), 1710 (s), 1603 (s), 1491
(w), 1447 (w), 1338 (w), 1264 (w), 1125 (m), 1106 (m), 1058 (m), 865 (m), 755 (s), 697 (m)
cm-1. 1H NMR (400 MHz, CDCl3): δ 7.41 – 7.32 (m, 3H), 7.29 – 7.25 (m, 2H), 6.28
(d, J = 2.5 Hz, 1H), 6.21 (s, 1H), 6.02-5.91 (m, 1H), 5.35 (dq, J = 17.3, 1.5 Hz, 1H), 5.27
(dq, J = 10.5, 1.3 Hz, 1H), 4.99 (d, J = 2.5 Hz, 1H), 4.34 (ddt, J = 12.6, 5.4, 1.4 Hz, 1H), 4.26
(ddt, J = 12.7, 5.6, 1.3 Hz, 1H), 1.66 (s, 3H).

13

C NMR (100 MHz, CDCl3): δ 190.0, 158.8,

144.7, 133.2, 132.1, 128.84, 128.80, 126.1, 123.3, 120.8, 118.7, 86.5, 86.1, 68.6, 22.2. HRMS
(ESI+): m/z calc’d for C17H16O3Na+: 291.0992. Found: 291.0997.
3-(Benzyloxy)-6-(4-ethynylphenyl)-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (2.27o).
Dimer 2.24a (24 mg, 0.0860 mmol), benzyl alcohol (89 μL, 0.860 mmol, 10 equiv.), and CH2Cl2
(0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage ® microwave reaction vial,
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0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicone oil bath for 14 h.
1,4-Diethynylbenzene (217 mg, 1.72 mmol, 20 equiv.) and CH2Cl2 (344 μL) were added to the
sealed tube, and the reaction mixture was stirred until no solid was observed. The reaction
mixture was then subjected to microwave irradiation at 100 ºC for 35 min and immediately
purified by column chromatography (silica (10 g), 0% EtOAc/hexane to 15% EtOAc/hexane
gradient over 30 column volumes). Product fractions were concentrated to give 2.27o as an
orange oil (25.7 mg, 44% yield). Due to high value of 1,4-diethynylbenzene (2.28), fractions
containing it were also concentrated (174 mg, 89% recovery (195 mg would be 100% theoretical
yield of un-reacted product)). Rf = 0.28 in 15% EtOAc in hexanes. IR (thin film, KBr): 3287
(m), 3035 (w), 2981 (w), 2935 (w), 2106 (w), 1709 (s), 1600 (m), 1498 (m), 1455 (m), 1339 (m),
1264 (m), 1124 (s), 1058 (m), 867 (m), 734 (m), 697 (m) cm -1. 1H NMR (400 MHz, CDCl3): δ
7.45 (d, J = 8.4 Hz, 2H), 7.35 – 7.27 (m, 5H), 7.08 (d, J = 8.4 Hz, 2H), 6.30 (d, J = 2.5 Hz, 1H),
6.19 (s, 1H), 5.01 (d, J = 2.5 Hz, 1H), 4.93 (d, J = 12.1 Hz, 1H), 4.78 (d, J = 12.1 Hz, 1H), 3.15
(s, 1H), 1.60 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 189.7, 158.2, 144.7, 135.6, 133.6, 132.5,
128.8, 128.3, 127.5, 126.0, 124.3, 122.5, 121.4, 86.4, 86.2, 83.2, 78.6, 69.7, 22.0. HRMS
(ESI+): m/z calc’d for C23H18O3Na+: 365.1148. Found: 365.1150.
Synthesis of α-Hydroxytropolones via Acid-Mediated Debenzylation: Procedure A. To a
solution of 2.27f (25.6 mg, 0.0804 mmol) in CH2Cl2 (500 μL) was added methanesulfonic acid
(210 μL, 3.22 mmol, 40 equiv.). The reaction mixture was stirred for 1 h, at which time it was
quenched with phosphate buffer (pH 7, 15 mL), extracted with CH2Cl2 (3 x 10 mL), dried over
Na2SO4, filtered, and concentrated under reduced pressure to yield 2.6a as a reddish brown oil
(19.0 mg, >95% crude yield). The 1H NMR for 2.6a was consistent with previously reported
data.55 1H NMR (400 MHz, CDCl3): δ 7.58 (s, 1H), 7.50 (s, 1H), 7.48 – 7.35 (m, 3H),
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7.25 – 7.21 (m, 2H), 2.26 (s, 3H). Procedure B. To a solution of 2.27f (25 mg, 0.0785 mmol) in
CH2Cl2 (1 mL) was added Amberlyst® 15 (4.7 mmol/g, 671 mg, 3.14 mmol, 40 equiv.). The
reaction mixture was stirred for 16 h, at which time the Amberlyst was washed with CH2Cl2
(5 x 2 mL). The Amberlyst was then stirred in phosphate buffer (pH 7, 15 mL) for 10 min, and
the aqueous layer was extracted with EtOAc (5 x 10 mL). Combined organics were dried over
Na2SO4, filtered, and concentrated under reduced pressure to yield 2.6a as a light brown oil
(11.6 mg, 65% yield). The 1H NMR for 2.6a was consistent with previously reported data. 55
1

H NMR (400 MHz, CDCl3): δ 7.58 (s, 1H), 7.50 (s, 1H), 7.48 – 7.35 (m, 3H), 7.25 – 7.21

(m, 2H), 2.26 (s, 3H).
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Figure 2.2. 1H NMR spectrum of compound 2.24a in CDCl3.
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Figure 2.3. 1H NMR spectrum of compound 2.24b in CDCl3.
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Figure 2.4. 13C NMR spectrum of compound 2.24b in CDCl3.
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Figure 2.5. 1H NMR spectrum of compound 2.27a in CDCl3.
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Figure 2.6. 13C NMR spectrum of compound 2.27a in CDCl3.
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Figure 2.7. 1H NMR spectrum of compound 2.27b (Method A) in CDCl3.
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Figure 2.8. 1H NMR spectrum of compound 2.27b (Method B) in CDCl3.
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Figure 2.9. 13C NMR spectrum of compound 2.27b in CDCl3.
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Figure 2.10. 1H NMR spectrum of compound 2.4h in CDCl3.
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Figure 2.11. 13C NMR spectrum of compound 2.4h in CDCl3.
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Figure 2.12. 1H NMR spectrum of compound 2.27c in CDCl3.
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Figure 2.13. 13C NMR spectrum of compound 2.27c in CDCl3.
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Figure 2.14. 1H NMR spectrum of compound 2.27d in CDCl3.
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Figure 2.15. 13C NMR spectrum of compound 2.27d in CDCl3.

98

Figure 2.16. 1H NMR spectrum of compound 2.27e in CDCl3.
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Figure 2.17. 13C NMR spectrum of compound 2.27e in CDCl3.
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Figure 2.18. 1H NMR spectrum of compound 2.27f in CDCl3.
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Figure 2.19. 13C NMR spectrum of compound 2.27f in CDCl3.
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Figure 2.20. 1H NMR spectrum of compound 2.27g in CDCl3.
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Figure 2.21. 13C NMR spectrum of compound 2.27g in CDCl3.
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Figure 2.22. 1H NMR spectrum of compound 2.27h in CDCl3.
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Figure 2.23. 13C NMR spectrum of compound 2.27h in CDCl3.
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Figure 2.24. 1H NMR spectrum of compound 2.27i in CDCl3.
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Figure 2.25. 13C NMR spectrum of compound 2.27i in CDCl3.
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Figure 2.26. 1H NMR spectrum of compound 2.4i in CDCl3.
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Figure 2.27. 1H NMR spectrum of compound 2.4i in CDCl3.
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Figure 2.28. 1H NMR spectrum of compound 2.27j in CDCl3.
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Figure 2.29. 13C NMR spectrum of compound 2.27j in CDCl3.
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Figure 2.30. 1H NMR spectrum of compound 2.27k in CDCl3.
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Figure 2.31. 13C NMR spectrum of compound 2.27k in CDCl3.
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Figure 2.32. 1H NMR spectrum of compound 2.27l in CDCl3.
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Figure 2.33. 13C NMR spectrum of compound 2.27l in CDCl3.
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Figure 2.34. 1H NMR spectrum of compound 2.27m in CDCl3.
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Figure 2.35. 13C NMR spectrum of compound 2.27m in CDCl3.
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Figure 2.36. 1H NMR spectrum of compound 2.27n in CDCl3.
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Figure 2.37. 13C NMR spectrum of compound 2.27n in CDCl3.
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Figure 2.38. 1H NMR spectrum of compound 2.27o in CDCl3.
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Figure 2.39. 13C NMR spectrum of compound 2.27o in CDCl3.
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Figure 2.40. 1H NMR spectrum of recovered alkyne 2.28 in CDCl3.
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Figure 2.41. 1H NMR spectrum of compound 2.6a (Procedure A) in CDCl3.
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Figure 2.42. 1H NMR spectrum of compound 2.6a (Procedure B) in CDCl3.
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Chapter III
A Traceless Solid-Phase Synthesis of α-Hydroxytropolones
3.1. Solid-Supported Synthesis of Small Molecule Libraries
Solid-phase organic synthesis (SPOS), in which compounds are assembled on insoluble
polymer resin beads, has revolutionized synthetic organic chemistry since first introduced by
Merrifield in 1963.40a,74 Solid-phase techniques possess two major advantages over traditional
procedures in solution. First, resin-bound products can simply be isolated by washing away
reagents or impurities from the supported material, allowing the use of excess reagents to drive
reactions to completion. Secondly, the overall time scale for solid-phase synthesis is significantly
reduced due to its ease of purification and amenability to automation. Though primarily
associated with peptide, nucleic acid, and carbohydrate chemistry, solid supports have been
utilized in the combinatorial synthesis of small molecule drugs and natural products. To gain
access to these compound libraries, novel polymer resins, traceless linkers, and automated
technologies were discovered and developed. These solid-phase strategies and innovations are
extensively detailed in several reviews, 40a,74 and hence the current discussion will highlight only
a few examples.
3.1.1. Ellman’s Library Synthesis of 1,4-Benzodiazepin-2-ones
1,4-Benzodiazepin-2-ones are the class of compounds in which the term “privileged
scaffold’ was first applied.41 Though they demonstrate an expansive therapeutic profile that
includes coronary vasodilation and viral inhibition, most of the biological activity of these
molecules can be attributed to their effects on the central nervous system. 75 In one of the first
reports outlining the combinatorial synthesis and biological testing of small molecule libraries,
Ellman and co-workers described a solid-phase approach to produce 1,4-benzodiazepin-2-one
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analogs (Scheme 3.1).76 The compound collection was constructed by initially attaching
aminobenzophenone derivatives to a solid support via a (4-(hydroxymethyl)phenoxy)acetic acid
(HMP) linker (3.1 → 3.2).76,77 The resin-bound intermediate 3.2 was then reacted with Fmocprotected amino acid fluoride to create compound 3.3. After Fmoc deprotection, ring closure on
3.3 was induced by an acid-mediated condensation reaction, giving molecule 3.4. Alkylation of
anilide 3.4 was achieved in the presence of lithiated 5-phenylmethyl-2-oxazolidinone.76 Finally,
the 1,4-benzodiazepine with four points of functionality was cleaved in acidic conditions. The
Ellman group prepared a 192-member library using this synthetic route and performed biological
screening on targets such as cholecystokinin (CCK) receptor A, which is a protein implicated in
gastrointestinal cancer, neuroprotection, and appetite satiety. 76b The work would stimulate
further studies on the therapeutic potential of 1,4-benzodiazepines as a whole.40a,74
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3.1.2. Nicolaou’s Combinatorial Synthesis of 2,2-Dimethylbenzopyrans
At the turn of the millennium, Nicolaou and co-workers reported an extremely thorough
combinatorial synthesis of the privileged substructure 2,2-dimethylbenzopyrans.42 Natural
products with the benzopyran structural motif exhibit antitumor, antimicrobial, and antiinflammtory activity and interact with a plethora of biological targets. 40a,42a,78,79 The synthetic
strategy implemented by the Nicolaou group entails the attachment of an ortho-prenylated
phenol (3.7) to a polymer support through a traceless selenium linker (Scheme 3.2).42 The
resulting resin-bound intermediate 3.8 then undergoes a 6-endo-trig cyclization to furnish the
benzopyran core (3.9), which can be derivatized using an array of chemical modifications (e.g.
organometallic additions, condensations, annulations, etc.). The compound is finally cleaved via
selenium oxidation, which facilitates a spontaneous syn-elimination at room temperature to
produce the benzopyran product (3.10 → 3.12). Nicolaou and coworkers would go on to
generate a 10,000-member library of these molecules in just eight days by combining the
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traceless solid-phase route with optically encoded split-and-pool techniques.42b Biological
evaluation of the benzopyran library revealed a high hit rate for a diverse range of targets. 79
3.1.3. Merck’s Solid-Phase Synthesis of 2-Arylindole Derivatives
The indole structure is a near-ubiquitous subunit of biologically active natural products
and pharmaceuticals, and the scope of its physiological effects is astronomical. Considering its
vast therapeutic potential, a number of research groups have described combinatorial syntheses
towards indole-derived drugs.40a,74 For example, Merck reported the construction of a 128,000member 2-arylindole library in order to search for G-protein-coupled receptor (GPCR) ligands.80
The group’s synthetic strategy initially entailed the anchoring of arylalkyl keto acids to a
sulfonamide resin (3.13 → 3.14, Scheme 3.3). The indole core was then generated through a
cyclization reaction with arylhydrazines in the presence of a Lewis acid (i.e. Fischer indole
synthesis).80,81 At this stage, up to 400 unique combinations for 3.15 were possible due to the
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incorporation of 20 distinct derivatives of each building block. The resin-bound molecule was
separated into 80 equal portions, where the sulfonamides were subsequently alkylated with
Mitsunobu conditions and displaced by 80 individual amines (3.15 → 3.16). After recombining
the compound pools (now with 32,000 possibilities), it was split into two equal portions,
whereby 128,000 molecules were produced through the creation of one library containing amides
(3.16) and the other consisting of amines (3.17). Physiological evaluation of the 2-arylindoles
resulted in multiple hits for several GPCRs, and led Merck to advance the program towards the
discovery of clinical candidates.80
3.2. The Solid-Phase Synthesis of αHTs
3.2.1. Leveraging Three-Component Oxidopyrylium Cycloaddition to Incorporate Solid Supports
As discussed previously, our laboratory discovered a three-component oxidopyrylium
cycloaddition that generates new oxabicyclic products through alcohol incorporation into
oxidopyrylium ylides (3.18 → 3.20, Scheme 3.4A).71 Furthermore, benzyl alcohol-derived
oxabicyclic intermediates generated from this reaction can be directly converted to αHTs when
subjected to methanesulfonic acid (3.20 → 3.21g). Given the prevalence of solid supports in
organic synthesis (reviewed above), we integrated a polystyrene-bound benzyl alcohol into our
αHT route by utilizing the three-component oxidopyrylium cycloaddition (Scheme 3.4B).82 This
resin possesses a major advantage over more widely used derivatives, such as Wang resin, in that
no additional components appear in solution upon cleavage (i.e. traceless). Therefore, the entire
procedure

grants

access

to

assay-ready

compounds

without

necessitating

column

chromatography.
The protocol was conducted in a sealed vessel, where polystyrene-supported benzyl
alcohol was lightly stirred in a solution of triflate salt 3.24 and base at 60 oC overnight (Table
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3.1). We speculate that this initial phase forms an oxidopyrylium heterodimer (3.25c and/or
3.25d) according to the known rapid dimerization processes of oxidopyrylium ylides. 49a
However, more mechanistic data is required to eliminate the possibility that the cross-linked
homodimer 3.25b acts as an intermediate. After completion of the overnight alcohol
incorporation, an on-bead cycloaddition was facilitated by heating the reaction mixture at 100 oC
in the presence of alkynes (3.24 → 3.23).82 For liquid alkynes, the solvent and solutes were
removed from the system prior to alkyne addition to increase the efficiency of the reaction
(Table 3.1, Procedure A). On the other hand, solid alkynes were directly added to the mixture
without expelling the solvent and solutes to allow for dissolution of the reagent (Procedure B).
The optimal cycloaddition reaction times were dictated by alkyne reactivity, as insufficient time
points gave increased amounts of allomaltol (3.26). Procedures with electronically poor alkynes
were generally complete within 2 hours, while more sluggish aromatic alkynes demanded ~5
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Entry

Alkyne

Procedure

Time (h)b

Yield (3.21:3.26:3.27)

1
2
3c
4a
5a
6a,c
7a
8
9
10c
11
12c
13
14
15c
16
17
18
19
20

R = COMe
R = COMe
R = COMe
R = COCy
R = COPh
R = COPh
R = CO(4-Ph)Ph
R = CO2Et
R = CO2Et
R = CO2Et
R = CO2Me
R = CO2Me
R = Ph
R = Ph
R = Ph
R = 4-CF3Ph
R = 4-CF3Ph
R = 1-Npth
R = 1-Npth
DMADd

A
A
A
B
B
B
B
A
A
A
A
A
A
A
A
A
A
A
A
A

1.5
2
2
2
2
2
3
1.5
1.5
1.5
1.5
1.5
4.5
5.5
5.5
4.5
5.5
4.5
5.5
1

8% 3.21a (9:1:0)
7% 3.21a
4% 3.21a (9:1:0)
11% 3.21b (15:1:4)
22% 3.21c (1:0:1)
6% 3.21c (5:0:1)
9% 3.21d (1:0:1)
6% 3.21e
9% 3.21e
4% 3.21e
6% 3.21f
6% 3.21f
7% 3.21g (9:1:0)
13% 3.21g (20:1:0)
6% 3.21g (5:1:0)
11% 3.21h (4:1:0)
6% 3.21h (4:1:0)
7% 3.21i (5:1:0)
6% 3.21i (15:1:0)
10% 3.27j

[a] CH2Cl2 and solutes not removed prior to addition of alkyne. [b] Time for step 2. [c] Reaction ran at twice
the scale of prior run. [d] DMAD = Dimethyl acetylenedicarboxylate.
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hours of heating for maximum output. Lastly, besides allomaltol and trace baseline
contaminants, furan byproducts (3.27) emerging from acid-mediated ring-opening/cleavage were
the only other impurities observed. As expected from previous reports, furan 3.27j was the major
product when dimethyl acetylenedicarboxylate (DMAD) was used for the process. 49b
From 33 mg of polystyrene-supported benzyl alcohol and 50 mg of triflate salt 3.24,
between 1-5 mg of various αHTs were obtained, corresponding to approximately 5-10% yield
based on resin loading (Table 3.1).82 Though large quantities of alkyne (400-500 mg) were
required for the cycloaddition reaction, the overall process is highly time efficient and bypasses
the need for chromatographic purification. As many as 8 αHTs were generated in parallel over a
single 24 hour period during our studies, with enough material being collected to determine
product formation and purity level by 1H NMR and perform several bioassays. Thus, despite the
low overall yields, the protocol may serve as an important tool in the rapid library synthesis of
αHTs for biological screening purposes.
3.2.2. Utilizing Solid-Phase αHT Synthesis as a Screening Tool for Biological Studies
Considering that αHTs are capable of binding to and inhibiting a variety of dinuclear
metalloenzymes,44 we directed our focus towards applying the solid-phase platform as a
screening tool for discovering potent inhibitors. A very promising target for αHTs is HIV
ribonuclease H (RNase H), against which the natural products β-thujaplicinol and manicol have
illustrated IC50 values of 200 nM and 600 nM, respectively.45a,45e HIV RNase H is an enzyme
located on the C-terminal domain of HIV reverse transcriptase (RT). 83 The RNase H active site
works in conjunction with the DNA polymerase of HIV RT to facilitate viral genomic
replication. Though a majority of treatments on the market inhibit the polymerase activity, the
RNase H domain remains clinically unexploited. However, due to the emergence of resistant
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HIV RNase H inhibitory data for solution and solid-phase αHTs
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Figure 3.1. Plot of HIV RNase H inhibitory data for solution and solid-phase αHTs.

viral variants, significant efforts are underway to identify viable drug candidates for HIV RNase
H.84 Our newly developed solid-supported synthesis has potential utility towards the increased
throughput of αHT-derived leads for this enzyme. Thus, we experimentally evaluated the assayready nature of the solid-supported library against HIV RNase H.82
In collaboration with Le Grice and co-workers, we began by measuring αHT inhibition
with a fluorescence resonance energy transfer (FRET) endpoint to monitor the RNase H activity
of HIV-1 RT (Figure 3.1).85 A majority of the compounds possessed a consistent inhibitory
potency, with typical IC50 values between 200 nM and 1 μM. When compared to the solution
phase counterparts, the solid-supported molecules were all within 2-3 fold difference, and also
within a standard deviation. Next, we analyzed the capability of the αHTs to stabilize HIV

134

HIV RNase H thermal stabilization assays for solution and
solid-phase αHTs
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Figure 3.2. Plot of HIV RNase H thermal stabilization data for solution and solid-phase αHTs.

RNase H against thermal denaturation with the use of differential scanning fluorimetry
(Thermofluor, Figure 3.2).86 Regardless of the corresponding impurities, all compounds
increased the melting point of the enzyme by 2-3 oC. In addition, those species that stabilized
the enzyme the least did so in both solution and solid-phase cases. Lastly, the protective effects
of the molecules were investigated in HIV-associated cellular assays.87 Only three derivatives
(i.e. 3.21a, 3.21e, 3.21f) demonstrated protective activity, as the trend was consistent for both
types of synthesis. Overall, these biological studies revealed that enzymatic and cell-based assays
are not severely impacted by the minor impurities observed with samples prepared from solidsupported chemistry. Hence, the synthetic method produces αHTs with assay-ready purity and
possesses potential utility in future screening endeavors.
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3.2.3. Limitations of Solid-Supported αHT Synthesis
The proof-of-principle synthetic and biological experiments outlined above illustrate that
the solid-supported platform is extremely time efficient and generates compounds with assayready purity. Nevertheless, improvements to the system are necessary for it to be completely
viable as a combinatorial technique for αHT synthesis. First, though yields for the process are
practical for biological screening, they are substantially low overall (i.e. ~5-20% yield for 9
substrates). These results are at least partially related to the heterogeneous nature of the reaction,
which would make complete alcohol exchange during the three-component oxidopyrylium
cycloaddition more difficult. For instance, prior optimization efforts for the solution phase
process demonstrated considerable increases in productivity when the purified dimer 3.25a
served as the ylide source.71 No such yield increases were observed when this strategy was
employed for the solid-supported synthesis (Scheme 3.5).82
On the other hand, some advantages did emerge when 3.25a was used in place of the
triflate salt/base combination. Through the elimination of the base, we easily recovered the
starting material by simply removing the supernatant liquid and evaporating the solvent.
Additionally, we could monitor the efficiency of incorporation by measuring the amount of
dimer re-isolated. For example, in Reaction A of Scheme 3.5, 16 out of 24 mg of 3.25a were
retrieved. Assuming that the remaining 8 mg of material is attached to the solid-support as
heterodimer, approximately half of that compound would be available for subsequent phases of
the synthetic sequence. In light of this data, the dimer concentration was increased to 4 equiv.
(8 equiv. based on monomeric ylide), and the incorporation step was stirred at room temperature
for 9 days (Scheme 3.5, Reaction B). We recovered 87% of 3.25a (104 out of 120 mg), and
improved our yields to 20% based on resin loading, providing some direction for future attempts
at optimization.
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Another major issue with the solid-phase platform is the inability to modify resin-bound
intermediates. Efforts at conducting chemical transformations on supported oxabicyclic
compounds, including Suzuki coupling or trifluoroacetic acid (TFA) deprotection, resulted in
unintended cleavage and no end product. These observations indicate that the polystyrene-bound
oxabicycle is generally unstable. We hypothesize that the decomposition is due to the electron
donating properties of the benzyl alcohol resin, which would potentially drive the intermediate
towards detrimental side-reactions or early deprotection.66a A possible solution to such a
dilemma is the use of different resins and/or linkers to stabilize the attachment of the
oxabicycle.74c These studies are currently underway to improve the solid-supported αHT
synthesis towards a completely functional combinatorial technique.
3.3. Conclusion
Our laboratory has leveraged a newly discovered three-component oxidopyrylium
cycloaddtion in the first reported solid-phase synthesis of αHTs. The method is extremely time
efficient and produces molecules with assay-ready purity, making it a useful tool for therapeutic
development. However, due to the low overall yields and an inability to modify on-bead, the
system still requires improvements to meet its full potential. Though endeavors are presently
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ongoing to address the issues with the solid-supported platform, the next chapter will detail an
approach that bypasses these limitations. Specifically, the discussion will describe the
incorporation of fluorous phase chemistry into our αHT route.
3.4. Experimental and Supporting Information
General Information: All starting materials and reagents were purchased from commercially
available sources and used without further purification, with exception of CH 2Cl2, which was
purified on a solvent purification system prior to reactions. 63 1H NMR shifts are measured using
the solvent residual peak as the internal standard (CHCl 3 δ 7.26), and reported as follows:
chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet
of doublet, q = quartet, m = multiplet), coupling constant (Hz), integration.

13

C NMR shifts are

measured using the solvent residual peak as the internal standard (CDCl 3 δ 77.16), and reported
as chemical shifts. Infrared (IR) spectral bands are characterized as broad (br), strong (s),
medium (m), and weak (w). Mass spectra were recorded on a spectrometer by electrospray
ionization (ESI) technique and time-of-flight (TOF) mass analyzer. Microwave reactions were
performed via the Biotage® Intiator (External IR Temperature Sensor). Where noted, reaction
products were purified via silica gel chromatography using a Biotage ® Isolera Prime, with
Biotage® SNAP 10 g cartridges, in a solvent system of ethyl acetate (EtOAc) in hexane.
Solution Phase Synthesis of 3-Methoxy-8-oxabicyclo[3.2.1]octenes:
Methyl 3-methoxy-5-methyl-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6-carboxylate (3.28f).
Triflate salt 3.24 (100 mg, 0.345 mmol), N,N-diisopropylaniline (81 μL, 0.414 mmol,
1.2 equiv.), and CH2Cl2 (0.46 M, 750 μL) were placed in a sealed tube reactor (Biotage ®
microwave reaction vial, 0.5-2 mL) and stirred until no solid was observed. Methyl propiolate
(307 μL, 3.45 mmol, 10 equiv.) was added to the sealed tube, and the reaction mixture was

138

subjected to microwave irradiation at 100 ºC for 20 min. The reaction mixture was then
immediately purified by column chromatography (silica (10 g), 0% EtOAc/hexane to 35%
EtOAc/hexane gradient over 22 column volumes), giving 3.28f as a yellow oil (54.8 mg, 71%
yield). Rf = 0.29 in 25% EtOAc in hexanes. IR (thin film, KBr): 3095 (w), 2954 (w), 2840 (w),
1712 (s), 1616 (m), 1604 (m), 1438 (w), 1323 (m), 1223 (m), 1127 (m), 1075 (m), 1035 (w), 873
(w), 859 (w), 752 (w) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.06 (d, J = 2.5 Hz, 1H), 6.05
(s, 1H), 4.98 (d, J = 2.5 Hz, 1H), 3.76 (s, 3H), 3.52 (s, 3H), 1.73 (s, 3H). 13C NMR (100 MHz,
CDCl3): δ 188.89, 163.49, 149.57, 145.27, 139.15, 119.53, 86.16, 85.75, 54.92, 52.32, 21.57.
HRMS (ESI+): m/z calc’d for C11H13O5+: 225.0757. Found: 225.0757.
Solution Phase Synthesis of α-Hydroxytropolones:
Methyl 4,6-dihydroxy-2-methyl-5-oxocyclohepta-1,3,6-trienecarboxylate (3.21f).
To a solution of bicycle 3.28f (54.8 mg, 0.244 mmol) in CH2Cl2 (0.16 M, 1.5 mL) was added
trifluoromethanesulfonic acid (86.3 μL, 0.978 mmol, 4 equiv.). The reaction mixture was
allowed to stir for 30 min, at which time it was quenched with phosphate buffer (pH 7, 10 mL),
extracted with CH2Cl2 (3 x 5 mL), dried over Na2SO4, filtered, and concentrated under reduced
pressure. The crude mixture was then dissolved in 33% HBr in acetic acid (2 mL), and heated to
reflux for 1.5 h. The reaction was cooled to room temperature, quenched with pH 7 phosphate
buffer (10 mL), and extracted with CH2Cl2 (3 x 5 mL), dried over Na2SO4, filtered, and
concentrated to give 3.21f as a brown solid (30.0 mg, 58% yield). MP = 137-141 °C. IR (thin
film, KBr): 3239 (br), 2963 (w), 1731 (s), 1544 (s), 1435 (m), 1400 (m), 1288 (s), 1214 (s),
1141 (m), 1100 (m), 1067 (w), 948 (w), 904 (w), 764 (w), 635 (w) cm-1. 1H NMR (400 MHz,
CDCl3): δ 7.73 (s, 1H), 7.48 (s, 1H), 3.93 (s, 3H), 2.56 (s, 3H). 13C NMR (100 MHz, CDCl3): δ
169.30, 168.82, 159.40, 156.96, 141.27, 132.64, 124.60, 120.92, 53.22, 25.97. HRMS (ESI+):
m/z calc’d for C10H11O5+: 211.0601. Found: 211.0602.
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Solid-Phase Synthesis of α-Hydroxytropolones Using Oxidopyrylium Triflate Salt:

General Procedure for Liquid Alkynes (Procedure A). Polystyrene supported benzyl alcohol
(3.5 mmol/g loading capacity, 1 equiv.) was placed in a sealed tube reactor (Biotage® microwave
reaction vial, 2-5 mL) and allowed to swell for 30 min in CH2Cl2. Triflate salt 3.24 (1.5 equiv.)
and N,N-diisopropylaniline (1.8 equiv.) were added to the sealed tube, and the reaction mixture
was gently stirred at 60 ºC for 14 h. The beads were drained of CH2Cl2, submerged in alkyne,
and heated to 100 ºC for various time points. After the reaction mixture was cooled to room
temperature, the beads were rinsed with CH2Cl2 (6 x 1 mL) and then resuspended in CH2Cl2.
Trifluoromethanesulfonic acid (4 equiv.) was added to the sealed tube, and the reaction mixture
was stirred at room temperature for 30 min. The reaction mixture was diluted with CH 2Cl2
(2 mL) and quenched with pH 7 phosphate buffer (10 mL). The aqueous layer was extracted with
CH2Cl2 (3 x 5 mL), and combined organics were dried over Na2SO4, filtered, and concentrated to
give αHT 3.21.
General Procedure for Solid Alkynes (Procedure B). Polystyrene supported benzyl alcohol
(3.5 mmol/g loading capacity, 1 equiv.) was placed in a sealed tube reactor (Biotage® microwave
reaction vial, 2-5 mL) and allowed to swell for 30 min in CH2Cl2. Triflate salt 3.24 (1.5 equiv.)
and N,N-diisopropylaniline (1.8 equiv.) were added to the sealed tube, and the reaction mixture
was gently stirred at 60 ºC for 14 h. Alkyne was added to the sealed tube, and the reaction
mixture was heated to 100 ºC for various time points. After the reaction mixture was cooled to
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room temperature, the beads were rinsed with CH2Cl2 (6 x 1 mL) and then resuspended in
CH2Cl2. Trifluoromethanesulfonic acid (4 equiv.) was added to the sealed tube, and the reaction
mixture was stirred at room temperature for 30 min. The reaction mixture was diluted with
CH2Cl2 (2 mL) and quenched with pH 7 phosphate buffer (10 mL). The aqueous layer was
extracted with CH2Cl2 (3 x 5 mL), and combined organics were dried over Na2SO4, filtered, and
concentrated to give αHT 3.21.
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Table 3.2. Detailed conditions and results for solid-phase αHT synthesis using oxidopyrylium triflate salt 3.24.
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Solid-Phase Synthesis of α-Hydroxytropolones Using Oxidopyrylium Dimer:

Procedure A. Polystyrene supported benzyl alcohol (3.5 mmol/g, 33 mg, 0.114 mmol, 1 equiv.)
was placed in a sealed tube reactor (Biotage® microwave reaction vial, 2-5 mL) and allowed to
swell for 30 min in CH2Cl2. Oxidopyrylium dimer 3.25a (24 mg, 0.086 mmol, 0.74 equiv.) was
added to the sealed tube, and the reaction mixture was gently stirred at 60 ºC for 14 h. The beads
were rinsed with CH2Cl2 (6 x 1 mL), and the supernatant liquid was collected (16 mg of 3.25a,
66% recovery). Ethyl propiolate (500 μL) was added to the sealed tube, and the reaction mixture
was heated to 100 ºC for 1.5 h. After the reaction mixture was cooled to room temperature, the
beads were rinsed with CH2Cl2 (6 x 1 mL) and then resuspended in CH2Cl2 (500 μL).
Trifluoromethanesulfonic acid (41 μL, 0.464 mmol, 4 equiv.) was added to the sealed tube, and
the reaction mixture was stirred at room temperature for 30 min. The reaction mixture was
diluted with CH2Cl2 (2 mL) and quenched with pH 7 phosphate buffer (10 mL). The aqueous
layer was extracted with CH2Cl2 (3 x 5 mL), and combined organics were dried over Na 2SO4,
filtered, and concentrated to give 3.21e (1.5 mg, 6% yield).
Procedure B. Polystyrene supported benzyl alcohol (3.5 mmol/g, 33 mg, 0.114 mmol, 1 equiv.)
was placed in a sealed tube reactor (Biotage® microwave reaction vial, 2-5 mL) and allowed to
swell for 30 min in CH2Cl2. Oxidopyrylium dimer 3.25a (120 mg, 0.428 mmol, 3.8 equiv.) was
added to the sealed tube, and the reaction mixture was gently stirred at 60 ºC for 14 h. The beads
were rinsed with CH2Cl2 (6 x 1 mL), and the supernatant liquid was collected (104 mg of 3.25a,
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87% recovery). Ethyl propiolate (500 μL) was added to the sealed tube, and the reaction mixture
was heated to 100 ºC for 1.5 h. After the reaction mixture was cooled to room temperature, the
beads were rinsed with CH2Cl2 (6 x 1 mL) and then resuspended in CH2Cl2 (500 μL).
Trifluoromethanesulfonic acid (41 μL, 0.464 mmol, 4 equiv.) was added to the sealed tube, and
the reaction mixture was stirred at room temperature for 30 min. The reaction mixture was
diluted with CH2Cl2 (2 mL) and quenched with pH 7 phosphate buffer (10 mL). The aqueous
layer was extracted with CH2Cl2 (3 x 5 mL), and combined organics were dried over Na2SO4,
filtered, and concentrated to give 3.21e (5 mg, 20% yield).
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Figure 3.3. 1H NMR spectrum of compound 3.28f in CDCl3.
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Figure 3.4. 13C NMR spectrum of compound 3.28f in CDCl3.
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Figure 3.5. 1H NMR spectrum of compound 3.21f in CDCl3.
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Figure 3.6. 13C NMR spectrum of compound 3.21f in CDCl3.
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Figure 3.7. 1H NMR spectrum of compound 3.21a (Entry 1) in CDCl3.
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Figure 3.8. 1H NMR spectrum of compound 3.21a (Entry 2) in CDCl3.
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Figure 3.9. 1H NMR spectrum of compound 3.21a (Entry 3) in CDCl3.
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Figure 3.10. 1H NMR spectrum of compound 3.21a (Solution Phase) in CDCl3.
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Figure 3.11. 1H NMR spectrum of compound 3.21b (Entry 4) in CDCl3.
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Figure 3.12. 1H NMR spectrum of compound 3.21b (Solution Phase) in CDCl3.
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Figure 3.13. 1H NMR spectrum of compound 3.21c (Entry 5) in CDCl3.
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Figure 3.14. 1H NMR spectrum of compound 3.21c (Entry 6) in CDCl3.
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Figure 3.15. 1H NMR spectrum of compound 3.21c (Solution Phase) in CDCl3.
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Figure 3.16. 1H NMR spectrum of compound 3.21d (Entry 7) in CDCl3.
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Figure 3.17. 1H NMR spectrum of compound 3.21d (Solution Phase) in CDCl3.
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Figure 3.18. 1H NMR spectrum of compound 3.21e (Entry 8) in CDCl3.
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Figure 3.19. 1H NMR spectrum of compound 3.21e (Entry 9) in CDCl3.
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Figure 3.20. 1H NMR spectrum of compound 3.21e (Entry 10) in CDCl3.
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Figure 3.21. 1H NMR spectrum of compound 3.21e (Solution Phase) in CDCl3.
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Figure 3.22. 1H NMR spectrum of compound 3.21f (Entry 11) in CDCl3.
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Figure 3.23. 1H NMR spectrum of compound 3.21f (Entry 12) in CDCl3.
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Figure 3.24. 1H NMR spectrum of compound 3.21f (Solution Phase) in CDCl3.

166

Figure 3.25. 1H NMR spectrum of compound 3.21g (Entry 13) in CDCl3.
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Figure 3.26. 1H NMR spectrum of compound 3.21g (Entry 14) in CDCl3.
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Figure 3.27. 1H NMR spectrum of compound 3.21g (Entry 15) in CDCl3.
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Figure 3.28. 1H NMR spectrum of compound 3.21g (Solution Phase) in CDCl3.

170

Figure 3.29. 1H NMR spectrum of compound 3.21h (Entry 16) in CDCl3.
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Figure 3.30. 1H NMR spectrum of compound 3.21h (Entry 17) in CDCl3.
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Figure 3.31. 1H NMR spectrum of compound 3.21h (Solution Phase) in CDCl3.
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Figure 3.32. 1H NMR spectrum of compound 3.21i (Entry 18) in CDCl3.
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Figure 3.33. 1H NMR spectrum of compound 3.21i (Entry 19) in CDCl3.
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Figure 3.34. 1H NMR spectrum of compound 3.21i (Solution Phase) in CDCl3.
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Figure 3.35. 1H NMR spectrum of compound 3.27j (Entry 20) in CDCl3.
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Figure 3.36. 1H NMR spectrum of recovered dimer 3.25a (Procedure A) in CDCl3.
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Figure 3.37. 1H NMR spectrum of compound 3.21e (Procedure A) in CDCl3.
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Figure 3.38. 1H NMR spectrum of recovered dimer 3.25a (Procedure B) in CDCl3.
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Figure 3.39. 1H NMR spectrum of compound 3.21e (Procedure B) in CDCl3.
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Chapter IV
A Fluorous Phase Approach to α-Hydroxytropolone Synthesis
4.1. An Introduction to Fluorous Phase Chemistry
Synthesis is universally restricted by the efficiency of the reactions being performed and
the ability to purify resultant mixtures. Though organic chemists have traditionally focused on
the effectiveness of transformations in solution, a number of techniques have recently emerged
that simplify purification. The most prevalent method entails the integration of solid supports
into a synthetic sequence (reviewed in Chapter III).40a,74 A second, lesser known approach
started in the 1990s utilizes the unique interactions between perfluorinated molecules and other
reaction media (i.e. fluorous phase chemistry).88 Specifically, the higher the fluorine content a
compound possesses, whether it be solvent or reactant, the more insoluble the species becomes in
aqueous and organic environments (>60% typically produces complete partition). 89 However,
unlike in water, the miscibility of fluorous molecules in organic solvents depends on
temperature, as heated systems become increasingly monophasic. This distinct solubility profile
was pivotal to the early success of fluorous chemistry and has granted access to a plethora of
novel linkers, catalysts, scavengers, and purification technologies. 88
4.1.1. The Major Advantages of Fluorous Phase Synthesis
Fluorous synthesis successfully incorporates solution phase reaction conditions with a
phase-tag separation that relies on perfluoroalkyl chains instead of resins to facilitate
purification.88,90 The fluorous tags are chemically stable and typically have minor influence on
the reactivity of a molecule to which they are attached. In contrast to solid-phase synthesis,
fluorous reactions can be monitored by conventional analytical techniques (e.g. TLC, NMR, IR,
etc.) and can adapt literature procedures without severe alteration. Additionally, although
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fluorous molecules can be isolated through traditional methods, including chromatography,
distillation, and recrystallization, exclusive purification procedures exist that rely on selective
fluorine-fluorine interactions between the tagged compound and the surrounding media (Figure
4.1).89,91
The first approach takes advantage of the inherent immiscibility between fluorous
solvents and other fluids to isolate individual reaction components, otherwise known as fluorous
liquid-liquid extraction (FLLE, Figure 4.1A).89 Separations are generally achieved with
organic/fluorous biphasic systems or organic/aqueous/fluorous triphasic extractions when watersoluble reagents are used. Nevertheless, this process is geared toward heavier fluorous molecules
(>60% fluorine content) since they demonstrate an optimal partition coefficient between organic
and fluorous phases. Also, FLLE often requires expensive and environmentally destructive
fluorous solvents, such as perfluoroalkanes, which could make it prohibitive for large-scale
endeavors.
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The second purification method is a fluorous solid-phase extraction (FSPE, Figure
4.1B).91 As the name implies, the procedure involves the use of a fluorinated solid-phase
component, specifically in the form of fluorocarbon bonded silica gel (–SiMe2(CH2)2C8 F17,
FluoroFlash®). This stationary phase retains organic species to a much lower degree than
ordinary reverse-phase silica. Hence, organic compounds will rapidly pass through the column
with an appropriate eluent. On the other hand, the fluorous silica is extremely retentive to
fluorinated molecules and can even partition compounds based on fluorine content. For instance,
Curran employed FSPE to separate a series of molecules containing fluorous tags that ranged
from C3F7 to C10F21.91a However, the approach does not necessitate fluorous solvents to elute
reaction mixtures, as common organic and aqueous solvent media will suffice. 91 In particular,
nonfluorous compounds are eluted with fluorophobic solutions, such as 60% acetonitrile (ACN)
in H2O or 80% methanol (MeOH) in H2O, while MeOH or acetone will pass fluorinated species
through the column. Additionally, the fluorous silica can be recycled dozens of times, making
FSPE a more economically and environmentally friendly purification strategy than FLLE.
Overall, fluorous chemistry incorporates standard solution phase reaction conditions and
analytical techniques with simplified and highly selective purification procedures. Due to these
properties, fluorous supports have successfully been exploited in combinatorial library synthesis
and synthetic methods development. These efforts have been thoroughly detailed in several
reviews,88 and thus the current discussion will highlight only a few examples to illustrate the
power of the fluorous phase platform.
4.1.2. Curran’s and Zhang’s Fluorous Combinatorial Synthesis of Mappicine Analogs
Nothapodytine B (4.1, Figure 4.2) is a natural product isolated from Nothapodytes
foetida that displays potent cytotoxicity in human KB lines92 and antiviral activity against
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HSV-1, HSV-2, and human cytomegalovirus (HCMV).93 The molecule is an oxidized analog of
the Mappa foetida alkaloid mappicine (4.2)94 and a decarboxylated derivative of camptothecin
(4.3), an effective DNA topoisomerase I inhibitor.95 In the early 2000s, the Curran and Zhang
groups reported the fluorous mixture synthesis of a 560-member mappicine analog library
(Scheme 4.1).96 The team employed a fluorous tagging system, where seven pyridinyl alcohols
were paired with a series of silyl fluorous tags possessing different chain lengths (4.4 → 4.5).96,97
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iodination/demethylation reactions to generate tagged pyridones (4.6).96 After splitting the
resulting mixture into eight portions, N-alkylation with eight distinct propargyl bromides was
conducted in parallel (4.6 → 4.7). The following eight pools were then separated into 10 portions
for parallel radical tandem cyclization with 10 isonitriles to produce 80 mixtures of fluorous
tagged mappicine analogs (4.7 → 4.8). Subsequently, fluorous HPLC was used to isolate the
individual components from each pool on the basis of the fluorine content the tags provide. A
total of 560 pure mappicine derivatives (4.9) were obtained after silyl deprotection.
Curran’s and Zhang’s combinatorial synthesis of mappicine analogs demonstrates that
fluorous phase techniques can be leveraged to separate individual, pure products after a reaction
process involving a mixture of organic molecules. Generally, solution phase reactions performed
on organic mixtures are highly efficient and demonstrate favorable reaction kinetics.
Nevertheless, the overall procedures can be exceedingly difficult to achieve due to timeconsuming challenges that emerge with the analysis, identification, and separation of each
mixture component. The group’s fluorous supported route bypassed these dilemmas and granted
access to a pure library of compounds that was adequately evaluated in biological systems. 98
Moreover, the strategy accommodated key reaction steps that could not be optimized on a solidphase platform.96
4.1.3. Zhang’s Fluorous Synthetic Method Towards Novel Fused Heterocyclic Ring Systems
Zhang and co-workers utilized a fluorous phase approach to generate three novel triaza
tricyclic and tetracyclic ring systems.99 The reaction method began with the synthesis of proline
derivative 4.13 from a one-pot, three-component [3 + 2] cycloaddition between a fluorous amino
ester (4.10), an N-alkylmaleimide (4.11), and a benzaldehyde (4.12, Scheme 4.2). This process
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was conducted under conventional or microwave heating and provided highly stereoselective
bicyclic products after FSPE. The proline analogs obtained were then used for diversity-oriented
synthesis (DOS) to produce hydantoin-, piperazinedione-, and benzodiazepine-fused ring
systems 4.15, 4.17, and 4.19 respectively (Scheme 4.3). The heterocyclic structures possessed
four stereocenters on the central pyrrolidine scaffold and up to four points of diversity (R 1-R4). In
addition, each compound contained privileged moieties which exhibit a wide range of
pharmaceutical utility.40a,100
Synthetically speaking, the hydantoin-fused molecules 4.15 were generated by first
reacting intermediates 4.13 with phenylisocyanate in the presence of catalytic amounts of
4-dimethylaminopyridine (DMAP) to provide 4.14.99 Next, compounds 4.14 were subjected to
base-promoted detagging and cyclization under microwave irradiation to give the final products.
Moving forward, the synthesis of the piperazinedione tricyclic species 4.17 was accomplished by
acylation of 4.13 with chloroacetylchloride, followed by substitution with amines to create 4.16.
The

linker

cleavage/cyclization

1,8-diazabicyclo[4.3.0]non-5-ene

reactions
(DBU)

on

using

4.16

were

microwave

then

promoted

irradiation.

Finally,

with
the

benzodiazepine scaffolds 4.19 were produced with a three-step sequence involving the
acylation/reduction of pyrrolidine 4.13 to intermediate 4.18, followed by cyclative linker
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cleavage in DBU to give the final derivatives. All of the intermediate reactions were purified by
FSPE, while the final steps for each analog class required FSPE and HPLC for maximum purity.
The Zhang group would further apply the chemistry developed for 4.15 and 4.19 in the fluorous
mixture synthesis of heterocyclic combinatorial libraries.101
4.2. The Fluorous Phase Synthesis of αHTs
As previously reviewed, we recently discovered a three-component oxidopyrylium
cycladdition that generates new oxabicyclic compounds through alcohol incorporation (Scheme
4.4A).71 Additionally, benzyl alcohol-derived oxabicyclic intermediates produced from this
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reaction can be directly converted to αHTs when subjected to methanesulfonic acid (Scheme
4.4B). Considering this information, we developed a solid-phase synthesis of αHTs utilizing
polystyrene-supported benzyl alcohol (Scheme 4.4C).82 The method is extremely time efficient
(i.e. a batch of 8 molecules produced over a 24 hour period) and provides compounds with assayready purity. However, improvements to the system are necessary to reach its full potential as a
combinatorial technique for αHT synthesis. First, though yields for the process are practical for
biological screening, they are substantially low overall (i.e. 5-20% yield for 9 substrates).
Secondly, the platform does not permit the modification of resin-bound intermediates, as
conditions for both Suzuki coupling and trifluoroacetic acid (TFA) deprotection cause
unintended cleavage (results not reported).
In order to address the issues corresponding with solid-phase synthesis, we turned our
attention to a fluorous phase approach. As outlined above, fluorous chemistry allows the
successful integration of solution phase reaction conditions and provides the ability to monitor
reactions through conventional analytical methods that cannot be performed on resin-bound
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molecules.88 Moreover, in relation to traditional organic synthesis, fluorous tagged compounds
can be purified easily and efficiently by exclusive techniques based on fluorine-fluorine
interactions (i.e. FLLE and FSPE).88-91 The following describes our attempts at synthesizing
αHTs by employing fluorous supported synthesis.
4.2.1. Fluorous Tag Incorporation and Cleavage
The integration of fluorous phase chemistry into our synthetic route poses three
challenges: 1) verify that fluorous tagged alcohols could successfully be incorporated into
oxabicyclic products, 2) assess how well the tagged compounds work with fluorous separation
techniques, and 3) demonstrate the capability to remove the tagged segment and form the final
product. Our studies began with the preparation of the fluorous tagged benzyl alcohol derivative
4.27, which can be generated in high yields through a previously reported approach. 102
Generally, the three-component oxidopyrylium cycloaddition is conducted under sealed
conditions with a surplus of alcohol (5 equivalents in relation to monomeric ylide) to drive the
incorporation.71 Considering the large molecular weight of 4.27, slight modifications to our
originally optimized procedure were required (Scheme 4.5A). For instance, the quantity of
alcohol was reduced (i.e. stoichiometric with monomeric ylide) to avoid excessive use of starting
material. Also, the incorporation time was increased to accommodate the lower alcohol
concentration. We were able to synthesize the fluorous tagged oxabicyclic compound 4.28a with
a 34% yield using these adjustments, which is consistent for aryl-containing products obtained
through the previously described method.
However, when larger scale experiments were performed under these sealed conditions,
reaction times were significantly increased, yielding little to no incorporation after 6 days.
Taking into account our original mechanistic hypothesis for the three-component oxidopyrylium
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cycloaddition,71 we speculated that the lack of conversion was due to the increased generation of
MeOH that accompanies the scaled up procedure. Since MeOH is more prevalent and trapped
within the reactor, the equilibrium of the alcohol incorporation is driven significantly from the
fluorous tagged ylide back to 4.21. In order to remove the MeOH byproduct from the reaction,
the solvent system was changed to a 2:1 mixture of carbon tetrachloride (CCl 4) and
perfluoromethylcyclohexane (C7F14) and the vessel was exposed to a light stream of argon
(Scheme 4.5B). This solvent combination was chosen not only for its ability to dissolve the
quantities of fluorous tagged alcohol necessitated by the reaction but for its higher boiling point
(76 oC for both solvents) that supersedes MeOH (64.7 oC). The boiling temperature, along with
the argon flow, allows for the evaporation of MeOH without drying out the reaction. Thus, the
equilibrium of the alcohol incorporation is shifted towards the product and the reaction time is
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decreased. With these scale-up alterations, compound 4.28a was generated in a 38% yield in
approximately 2 days, demonstrating a similar yield to its smaller scale counterpart.
Moving forward, we wanted to test if the newly obtained oxabicyclic product could be
purified by fluorous phase separation techniques. Since the fluorine content of 4.28a (<50%) is
not acceptable for FLLE,89 we chose FSPE as our starting point. Compound 4.28a was purposely
contaminated with the non-fluorinated derivative 4.29a and loaded onto a 4 gram column of
standard tridecafluoro functionalized silica gel (SiliaBond® Tridecafluoro, Figure 4.3).
Following a typical FSPE procedure,91 4.29a was extracted with 80% MeOH in water and 4.28a
was retrieved with acetone. Overall, 94% of 4.28a and 93% of 4.29a were recovered, proving
that FSPE can be used to purify the fluorous tagged oxabicycles.
After demonstrating that it is possible to incorporate fluorous tagged alcohols into our
oxabicyclic products and purify them with fluorous extraction, we directed our attention towards
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the ring-opening/debenzylation phase of 4.28a to αHT 4.24a. In our previous report,71 the
benzyl-derived oxabicycle 4.23a underwent both ring-opening and debenzylation when exposed
to liquid- and solid-phase methanesulfonic acid. Upon subjecting 4.28a to these conditions, we
only observed the ring-opening product, as fluorous tagged tropolone 4.30a was isolated in
quantitative yields (Scheme 4.6). The fluorous segment was removed upon returning to our
original demethylation procedure (i.e. HBr in acetic acid), and a crude mixture of αHT 4.24a and
fluorous tagged impurities was obtained. Considering the high fluorine content of the benzylated
byproducts (>50%), both FSPE and FLLE were successfully used to purify the final product.
With regard to the latter purification method, a 50% solution of methoxyperfluorobutane
(HFE-7100) in C7F14 proved very effective in separating unwanted contaminants from the αHT
(refer to Supp. Info.). Compound 4.24a was obtained in 85% yield after FSPE and 95% yield
after FLLE.
4.2.2. The Chemical Modification of Fluorous Tagged Oxabicyclic and Tropolone Intermediates
We found the result described above very promising since it indicates that the electron
deficient nature of the fluorous tag introduces stability to our intermediates in harsh media. The
added stabilization would allow us to perform modification at multiple stages of our synthetic
route, unlike in the case of solid-phase synthesis. To test this hypothesis, we synthesized a pair of
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fluorous tagged oxabicycles (4.28j and 4.28k) with functional handles to attempt a series of
experiments involving metal catalyzed cross coupling and amide coupling.
Initially, various palladium catalyzed Suzuki reactions, including systems with
Pd(OAc)2/JPhos or Pd(PPh)4, were performed on compound 4.28j with benzyl and naphthyl
boronic acids to complete conversion. The resulting oxabicycles were subjected to ringopening/debenzylation conditions, and the corresponding αHTs were synthesized and confirmed
through NMR analysis (results not shown). Unfortunately, pure final compounds could not be
obtained with these procedures due to the presence of phosphine derived byproducts. Such
impurities are not very soluble in the nonfluorous mobile phase of FSPE (80% MeOH in water or
70% ACN in water), and hence contaminate the fluorous eluent (acetone or MeOH) to the
detriment of subsequent reaction purity.
In order to bypass this issue, we moved towards Suzuki conditions that utilize water
soluble SPhos as the activating ligand (Scheme 4.7).27b The phosphine byproducts were
significantly removed from the intermediate but large amounts of solvent were still necessary
during FSPE to achieve adequate purity (refer to Supp. Info.). However, the resulting bisphenyl
oxabicyclic intermediate was successfully converted to pure αHT 4.24j after ringopening/debenzylation. Studies on making purification for metal-catalyzed cross-coupling
reactions on our fluorous tagged oxabicyclic products more efficient are currently ongoing.
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Nevertheless, this data demonstrates that modification through a fluorous phase approach is more
tolerated than our previously reported solid-phase synthesis.
Moving forward to amide coupling reactions, compound 4.28k was used as a starting
point to generate fluorous tagged intermediates with carboxylic acid functionalities (Scheme
4.8). Through a simple reaction sequence involving an acid-mediated deprotection, followed by a
ring-opening, 4.28k was converted to oxabicycle 4.28l and tropolone 4.30l near quantitatively.
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Each of these carboxylic acid derivatives was reacted with piperidine in the presence of PyBOP
and N,N-diisopropylethylamine (DIPEA) to either produce compound 4.28m in 59% yield or
4.30m in 84% yield after FSPE and hexane wash (Scheme 4.9). The corresponding αHT was
then obtained by two different paths: 1) ring-opening/debenzylation of oxabicycle 4.28m and 2)
debenzylation of tropolone 4.30m. Both steps were purified by FLLE to separate the fluorous
tagged impurities from the final product 4.24m, demonstrating a divergent synthetic pathway to
access an amide-derived αHT with fluorous phase chemistry.
Taking into account that a secondary amine was used during our initial amide
modification experiments, we tested if primary amines could also undergo a divergent approach
to αHTs (Scheme 4.10). When oxabicycle 4.28l was subjected to PyBOP coupling conditions
with 1-naphthylmethylamine, major decomposition was observed and the anticipated amide

196

could not be obtained after FSPE. On the other hand, tropolone 4.30l was successfully converted
to the corresponding amide-derivative 4.30n using the PyBOP procedure outlined above and
taken further to αHT 4.24n in high yields for both steps. Thus, even though the oxabicycle route
is limited to more sterically hindered secondary amines, the tropolone pathway can be used to
achieve the coupling of both types of amines.
4.3. Conclusion
In summary, we have demonstrated the first fluorous phase synthesis of αHTs utilizing
three-component oxidopyrylium cycloaddition chemistry. In a prior report, we have shown that
this reaction could be leveraged towards incorporation of solid-phase resins.82 Though the
method was time efficient and yielded assay-ready compounds, our solid-supported synthesis
resulted in low yields and an inability to modify intermediates while attached to the resin. By
incorporating fluorous tags instead of solid supports, we have significantly improved reaction
output and generated intermediates that can undergo modification through metal catalyzed cross
coupling and amide coupling. Studies are currently ongoing to fully optimize this platform in
order to make it a combinatorial technique for αHTs.
4.4. Experimental and Supporting Information
General Information: All starting materials and reagents were purchased from commercially
available sources and used without further purification, with the exception of CH2Cl2, which was
purified on a solvent purification system prior to reactions. 63 1H,
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F, and 13C NMR shifts were

measured using the solvent residual peak as the internal standard and reported as follows:
chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet
of doublets, q = quartet, m = multiplet), coupling constant (Hz), integration. Infrared (IR)
spectral bands are characterized as broad (br), strong (s), medium (m), and weak (w). Mass
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spectra were recorded on a spectrometer by the electrospray ionization (ESI) technique with a
time-of-flight (TOF) mass analyzer. Microwave reactions were performed via the Biotage®
Initiator (external IR temperature sensor). Where noted, reaction products were purified via silica
gel chromatography using a Biotage ® Isolera Prime, with Biotage® SNAP Ultra 10 g or 25 g
cartridges, in a solvent system of ethyl acetate (EtOAc) in hexane. Fluorous solid-phase
extraction (FSPE) was performed using columns packed with SiliaBond® Tridecafluoro silica
gel.
Synthesis of Fluorous Tagged 3-Benzyloxy-8-Oxabicyclo[3.2.1]octenes:
5-Methyl-3-((4-(perfluorooctyl)benzyl)oxy)-6-phenyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one
(4.28a). Method A. Dimer 4.26 (24 mg, 0.0856 mmol), benzyl alcohol 4.27 (91 mg, 0.172 mmol,
2 equiv.), and CH2Cl2 (0.25 M, 344 μL) were placed in a sealed tube reactor (Biotage®
microwave reaction vial, 0.5-2 mL), and the reaction mixture was heated to 60 ºC in silicon bath
oil for 36 h. Phenyl acetylene (378 µL, 3.44 mmol, 40 equiv.) was added to the sealed tube, and
the reaction mixture was subjected to microwave irradiation at 100 ºC for 1 h. The reaction was
then immediately purified by column chromatography (silica (10 g), 0% EtOAc/hexane to 20%
EtOAc/hexane gradient over 23 column volumes), giving 4.28a as a yellow oil (43 mg, 34%
yield). Method B. Dimer 4.26 (200 mg, 0.714 mmol) and benzyl alcohol 4.27 (751 mg,
1.43 mmol, 2 equiv.) were placed in a sealed tube reactor (Biotage® microwave reaction vial,
10-20 mL) and the vessel was purged with argon (3x). Carbon tetrachloride (2.75 mL) and
perfluoromethylcyclohexane (1.38 mL) were added to the sealed reactor, and the reaction
mixture was heated to 60 ºC in silicon bath oil for 48 h under argon. Phenyl acetylene (3.14 mL,
28.6 mmol, 40 equiv.) was added to the sealed tube, and the reaction mixture was subjected to
microwave irradiation at 100 ºC for 2.5 h. The reaction mixture was evaporated and purified by
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column chromatography (silica (25 g), 0% EtOAc/hexane to 15% EtOAc/hexane gradient over
17 column volumes), giving 4.28a as a yellow oil (401.9 mg, 38% yield). FSPE Protocol A. A
Biotage® SNAP Ultra 10 g cartridge was filled with SiliBond® Tridecafluoro silica gel (4 g) and
preconditioned with 50% MeOH in H2O. Compound 4.28a (46.4 mg, 0.063 mmol) was
contaminated with 4.29a (13.5 mg, 0.056 mmol), and the mixture was loaded onto the cartridge
in CHCl3. The nonfluorous material was provided by elution with 80% MeOH in H2O (40 mL),
while the fluorous component was obtained by elution with acetone (40 mL). The resulting
fractions were then concentrated, giving 4.28a as a yellow oil (43.4 mg, 94% recovery) and
4.29a as a white solid (12.6 mg, 93% recovery). The cartridge was washed with MeOH (40 mL)
and acetone (40 mL) prior to reuse, and it was recycled up to 30 times. The 1H NMR for 4.29a
was consistent with previously reported data.49a Characterization of 4.28a. Rf = 0.27 in 15%
EtOAc in hexanes. IR (thin film, KBr): 3060 (w), 2981 (w), 2935 (w), 1712 (s), 1606 (s), 1492
(m), 1447 (m), 1420 (m), 1296 (s), 1211 (s), 1150 (s), 1059 (m), 868 (m), 754 (s), 697 (s), 657
(s) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.58 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H),
7.38 – 7.31 (m, 3H), 7.20 – 7.15 (m, 2H), 6.29 (d, J = 2.4 Hz, 1H), 6.24 (s, 1H), 5.02
(d, J = 2.5 Hz, 1H), 4.97 (d, J = 12.7 Hz, 1H), 4.85 (d, J = 12.7 Hz, 1H), 1.64 (s, 3H). 19F NMR
(376 MHz, CDCl3): δ -80.8 (t, J = 9.9 Hz, 3F), -110.7 (t, J = 14.5 Hz, 2F), -121.1 – -121.4
(m, 2F), -121.7 – -122.1 (m, 6F), -122.56 – -122.89 (m, 2F), -126.0 – -126.2 (m, 2F). 13C NMR
(100 MHz, CDCl3): δ 189.7 (s), 158.8 (s), 144.6 (s), 140.0 (s), 133.0 (s), 128.9 (s), 128.9
(t, J = 24.4 Hz), 128.8 (s), 127.4 (s), 127.4 (t, J = 6.4 Hz), 126.0 (s), 123.2 (s), 122.0 (s),
86.5 (s), 86.1 (s), 68.8 (s), 22.0 (s). HRMS (ESI+): m/z calc’d for C29H17 F17O3Na+: 759.0798.
Found: 759.0802.

199

6-(3-Bromophenyl)-5-methyl-3-((4-(perfluorooctyl)benzyl)oxy)-8-oxabicyclo[3.2.1]octa-3,6dien-2-one (4.28j). Dimer 4.26 (200 mg, 0.714 mmol) and benzyl alcohol 4.27 (751 mg,
1.43 mmol, 2 equiv.) were placed in a sealed tube reactor (Biotage® microwave reaction vial,
10-20 mL), and the vessel was purged with argon (3x). Carbon tetrachloride (2.75 mL) and
perfluoromethylcyclohexane (1.38 mL) were added to the sealed reactor, and the reaction
mixture was heated to 60 ºC in silicon bath oil for 36 h under argon. 1-Bromo-3-ethynylbenzene
(1.72 mL, 14.3 mmol, 20 equiv.) was added to the sealed tube, and the reaction mixture was
subjected to microwave irradiation at 100 ºC for 3 h. The reaction mixture was evaporated and
purified by column chromatography (silica (25 g), 0% EtOAc/hexane to 15% EtOAc/hexane
gradient over 27 column volumes), giving 4.28j as a yellow oil (366.7 mg, 32% yield). Due to
the high cost of 1-bromo-3-ethynylbenzene, fractions containing it were also concentrated
(2.029 g, 87% recovery (2.321 g would be 100% theoretical yield of unreacted product)).
Rf = 0.29 in 15% EtOAc in hexanes. IR (thin film, KBr): 3064 (w), 2982 (w), 2936 (w), 1713
(s), 1605 (s), 1588 (m), 1558 (m), 1473 (m), 1338 (m), 1295 (s), 1210 (s), 1151 (s), 1059 (m),
869 (s), 773 (s), 657 (s) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.58 (d, J = 8.3 Hz, 2H),
7.52 – 7.44 (m, 3H), 7.38 – 7.35 (m, 1H), 7.24 – 7.18 (m, 1H), 7.09 – 7.05 (m, 1H), 6.34
(d, J = 2.4 Hz, 1H), 6.23 (s, 1H), 5.02 (d, J = 2.5 Hz, 1H), 4.96 (d, J = 12.6 Hz, 1H), 4.85
(d, J = 12.6 Hz, 1H), 1.63 (s, 3H).
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F NMR (376 MHz, CDCl3): δ -80.8 (t, J = 9.5 Hz,

3F), -110.7 (t, J = 14.5 Hz, 2F), -121.2 (bs, 2F), -121.6 – -122.1 (m, 6F), -122.6 – -122.9 (m, 2F),
-126.0 – -126.3 (m, 2F).
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C NMR (100 MHz, CDCl3): δ 189.3 (s), 157.5 (s), 144.7 (s), 139.9

(s), 135.1 (s), 131.8 (s), 130.3 (s), 129.1 (s), 129.0 (t, J = 24.3 Hz), 127.4 (s), 127.4
(t, J = 6.5 Hz), 124.8 (s), 124.5 (s), 123.0 (s), 121.5 (s), 86.4 (s), 86.1 (s), 68.8 (s), 22.0 (s).
HRMS (ESI+): m/z calc’d for C29H16BrF17O3Na+: 836.9904. Found: 836.9907.
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tert-Butyl 5-methyl-2-oxo-3-((4-(perfluorooctyl)benzyl)oxy)-8-oxabicyclo[3.2.1]octa-3,6diene-6-carboxylate (4.28k). Dimer 4.26 (200 mg, 0.714 mmol) and benzyl alcohol 4.27
(751 mg, 1.43 mmol, 2 equiv.) were placed in a sealed tube reactor (Biotage® microwave
reaction vial, 10-20 mL), and the vessel was purged with argon (3x). Carbon tetrachloride
(2.75 mL) and perfluoromethylcyclohexane (1.38 mL) were added to the sealed reactor, and the
reaction mixture was heated to 60 ºC in silicon bath oil for 48 h under argon. tert-Butyl
propiolate (1.96 mL, 14.3 mmol, 20 equiv.) was added to the sealed tube, and the reaction
mixture was subjected to microwave irradiation at 100 ºC for 1 h. The reaction mixture was
evaporated and purified by column chromatography (silica (25 g), 0% EtOAc/hexane to 10%
EtOAc/hexane gradient over 24 column volumes), giving 4.28k as a white solid (550.5 mg, 51%
yield). MP = 109-112 ºC. Rf = 0.21 in 10% EtOAc in hexanes. IR (thin film, KBr): 3059 (w),
2982 (w), 2938 (w), 1703 (s), 1615 (m), 1604 (m), 1452 (w), 1370 (m), 1329 (m), 1300 (m),
1197 (s), 1146 (s), 1076 (m), 944 (m), 863 (m), 659 (s) cm -1. 1H NMR (400 MHz, CDCl3): δ
7.58 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H), 6.98 (d, J = 2.5 Hz, 1H), 6.15 (s, 1H), 5.01
(d, J = 2.5 Hz, 1H), 4.86 (d, J = 12.5 Hz, 1H), 4.79 (d, J = 12.5 Hz, 1H), 1.72 (s, 3H), 1.48
(s, 9H).
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F NMR (376 MHz, CDCl3): δ -80.7 (t, J = 9.9 Hz, 3F), -110.7 (t, J = 14.5 Hz, 2F),

-121.1 – -121.3 (m, 2F), -121.7 – -122.0 (m, 6F), -122.5 – -122.8 (m, 2F), -126.0 – -126.2
(m, 2F).
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C NMR (100 MHz, CDCl3): δ 188.7 (s), 162.2 (s), 151.1 (s), 143.8 (s), 139.9 (s),

137.6 (s), 128.9 (t, J = 24.4 Hz), 127.5 (s), 127.4 (t, J = 6.4 Hz), 121.9 (s), 86.0 (s), 85.6 (s), 82.4
(s), 68.6 (s), 28.2 (s), 21.4 (s). HRMS (ESI+): m/z calc’d for C28H21F17O5Na+: 783.1010. Found:
783.1011.
5-Methyl-2-oxo-3-((4-(perfluorooctyl)benzyl)oxy)-8-oxabicyclo[3.2.1]octa-3,6-diene-6carboxylic acid (4.28l). Oxabicycle 4.28k (435.8 mg, 0.573 mmol) and 50% trifluoroacetic acid
in CH2Cl2 (2.2 mL) were placed in a sealed tube reactor (Biotage® microwave reaction vial,
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2-5 mL), and the reaction mixture was subjected to microwave radiation at 70 ºC for 2 min. The
organic layer was concentrated under reduced pressure and then subjected to azeotropic removal
with CH2Cl2 (5 x 2 mL), resulting in a yellowish solid. The solid was washed with hexane
(5 x 4 mL) and dried under vacuum to give 4.28l as an off-white solid (396.7 mg, >95% yield).
MP = 144-146 ºC. Rf = 0.25 in 10% MeOH in CH2Cl2. IR (thin film, KBr): 3070 (w), 2989 (w),
2867 (br), 1708 (m), 1676 (s), 1616 (m), 1605 (m), 1422 (w), 1335 (m), 1280 (m), 1199 (s), 1147
(s), 1091 (m), 942 (m), 879 (m), 659 (m) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.59
(d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 2.5 Hz, 1H), 6.17 (s, 1H), 5.10
(d, J = 2.5 Hz, 1H), 4.84 (d, J = 12.3 Hz, 1H), 4.79 (d, J = 12.3 Hz, 1H), 1.77 (s, 3H). 19F NMR
(376 MHz, CDCl3): δ -80.9 (t, J = 9.9 Hz, 3F), -110.8 (t, J = 14.4 Hz, 2F), -121.3 (bs, 2F),
-121.8 – -122.1 (m, 6F), -122.8 (bs, 2F), -126.0 – -126.7 (m, 2F). 13C NMR (100 MHz, CDCl3):
δ 188.1 (s), 167.9 (s), 148.9 (s), 143.9 (s), 142.3 (s), 139.6 (s), 129.1 (t, J = 24.3 Hz), 127.6 (s),
127.4 (t, J = 6.4 Hz), 121.5 (s), 86.3 (s), 85.5 (s), 68.8 (s), 21.3 (s). HRMS (ESI+): m/z calc’d
for C24H13 F17O5Na+: 727.0384. Found: 727.0387.
5-Methyl-3-((4-(perfluorooctyl)benzyl)oxy)-6-(piperidine-1-carbonyl)-8-oxabicyclo[3.2.1]
octa-3,6-dien-2-one (4.28m). A solution of oxabicycle 4.28l (60 mg, 0.0852 mmol), PyBOP
(48.8 mg, 0.0937 mmol, 1.1 equiv.), and DIPEA (32.6 μL, 0.187 mmol, 2.2 equiv.) in CH2Cl2
(0.04 M, 2 mL) was stirred at room temperature for 20 min in a sealed tube reactor (Biotage ®
microwave reaction vial, 2-5 mL). Piperidine (9.3 μL, 0.0937 mmol, 1.1 equiv.) was then added
to the sealed vessel, and the reaction mixture was subjected to microwave radiation at 85 ºC for
5 min. The mixture was concentrated under reduced pressure and purified by FSPE as described
in Protocol A. The acetone layer was evaporated, producing a yellow solid. The solid was
washed with hexane (5 x 2 mL) to give 4.28m as a white solid (38.7 mg, 59% yield).
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MP = 173-175 ºC. Rf = 0.29 in 40% EtOAc in hexanes. IR (thin film, KBr): 3070 (w), 2942
(m), 2862 (m), 1711 (s), 1609 (s), 1445 (s), 1287 (s), 1212 (s), 1151 (s), 1089 (m), 1026 (m), 989
(m), 913 (w), 874 (m), 735 (m), 652 (m) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.58
(d, J = 8.3 Hz, 2H), 7.50 (d, J = 8.3 Hz, 2H), 6.35 (s, 1H), 6.29 (d, J = 2.4 Hz, 1H), 5.11
(d, J = 2.4 Hz, 1H), 4.85 (d, J = 12.2 Hz, 1H), 4.80 (d, J = 12.2 Hz, 1H), 3.67 – 3.45 (m, 4H),
1.76 – 1.66 (m, 2H), 1.65 – 1.49 (m, 7H). 19F NMR (376 MHz, CDCl3): δ -80.7 (t, J = 9.9 Hz,
3F), -110.7 (t, J = 14.4 Hz, 2F), -121.1 – -121.3 (m, 2F), -121.7 – -122.1 (m, 6F), -122.7 (bs, 2F),
-125.8 – -126.5 (m, 2F).
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C NMR (100 MHz, CDCl3): δ 188.3 (s), 163.6 (s), 150.7 (s), 143.9

(s), 140.1 (s), 128.8 (t, J = 24.5 Hz), 127.8 (s), 127.8 (s), 127.3 (t, J = 6.5 Hz), 123.6 (s), 87.4 (s),
87.1 (s), 68.7 (s), 47.9 (s), 42.9 (s), 27.0 (s), 25.8 (s), 24.7 (s), 20.7 (s). HRMS (ESI+): m/z
calc’d for C29H23F17NO4+: 772.1350. Found: 772.1352.
Synthesis of Fluorous Tagged Benzyloxy Tropolones:
2-Hydroxy-5-methyl-7-((4-(perfluorooctyl)benzyl)oxy)-4-phenylcyclohepta-2,4,6-trien-1one (4.30a). To a solution of 4.28a (135.2 mg, 0.184 mmol) in CH2Cl2 (0.16 M, 1.15 mL) was
added methanesulfonic acid (477 μL, 7.36 mmol, 40 equiv). The reaction mixture was stirred at
room temperature for 1 h, at which time it was quenched with phosphate buffer (pH 7, 0.1 M,
5 mL) and extracted with CHCl3 (3 x 5 mL). The organic layer was washed with brine (15 mL),
dried over Na2SO4, filtered, and concentrated under reduced pressure to yield a golden brown
solid. This solid was washed with hexane (5 x 2 mL) and dried under vacuum to give 4.30a as a
light brown solid (131.6 mg, >95% yield). MP = Decomposes at 155 ºC. IR (thin film, KBr):
3220 (br), 3029 (w), 2917 (w), 2858 (w), 1575 (m), 1564 (m), 1473 (m), 1384 (w), 1332 (m),
1199 (s), 1148 (s), 1116 (s), 912 (m), 765 (m), 703 (m), 656 (m) cm -1. 1H NMR (400 MHz,
CDCl3): δ 7.67 (d, J = 8.6 Hz, 2H), 7.63 (d, J = 8.7 Hz, 2H), 7.46 – 7.35 (m, 4H), 7.31 (s, 1H),
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7.24 – 7.20 (m, 2H), 5.39 (s, 2H), 2.18 (s, 3H).
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F NMR (376 MHz, CDCl3): δ -80.8

(t, J = 9.9 Hz, 3F), -110.6 (t, J = 14.3 Hz, 2F), -121.2 (bs, 2F), -121.6 – -122.1 (m, 6F),
-122.7 (bs, 2F), -126.0 – -126.2 (m, 2F). 13C NMR (100 MHz, CDCl3): δ 169.5 (s), 160.3 (s),
156.6 (s), 145.2 (s), 143.5 (s), 140.7 (s), 135.0 (s), 128.9 (t, J = 24.3 Hz), 128.7 (s), 128.2 (s),
127.9 (s), 127.6 (s), 127.6 (s), 127.5 (t, J = 6.5 Hz), 122.3 (s), 71.0 (s), 26.5 (s). HRMS (ESI+):
m/z calc’d for C29H18F17O3+: 737.0979. Found: 737.0982.
6-Hydroxy-2-methyl-5-oxo-4-((4-(perfluorooctyl)benzyl)oxy)cyclohepta-1,3,6-triene-1carboxylic acid (4.30l). To a solution of 4.281 (116.1 mg, 0.165 mmol) in CH2Cl2 (0.1 M,
1.42 mL) was added trifluoromethanesulfonic acid (58.2 μL, 0.659 mmol, 4 equiv). The reaction
mixture was stirred at room temperature for 30 min, at which time it was quenched with
phosphate buffer (pH 7, 1 M, 5 mL). The CH2Cl2 was drained and the remaining residue was
extracted with EtOAc (3 x 5 mL). All organics were collected, dried over Na 2SO4, filtered, and
concentrated under reduced pressure to give a yellow solid. The solid was washed with 50%
CH2Cl2 in hexanes (6 x 2 mL) and dried under vacuum to give 4.30l as a light yellow solid
(107.3 mg, 92% yield). MP = 163-166 ºC. IR (thin film, KBr): 3442 (br), 1699 (m), 1621 (w),
1570 (m), 1482 (w), 1382 (w), 1372 (w), 1299 (m), 1230 (s), 1201 (s), 1149 (s), 1111 (m), 1051
(w), 946 (w), 850 (w), 663 (m) cm-1. 1H NMR (400 MHz, Acetone): δ 7.85 (d, J = 8.2 Hz, 2H),
7.77 (d, J = 8.3 Hz, 2H), 7.57 (s, 1H), 7.49 (s, 1H), 5.50 (s, 2H), 2.56 (s, 3H).
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F NMR

(376 MHz, Acetone): δ -81.6 (t, J = 10.1 Hz, 3F), -110.7 (t, J = 14.5 Hz, 2F), -121.6 – -121.9
(m, 2F), -122.2 – -122.6 (m, 6F), -123.2 (bs, 2F), -126.6 – -126.9 (m, 2F). 13C NMR (100 MHz,
Acetone): δ 171.8 (s), 170.2 (s), 160.2 (s), 159.2 (s), 142.5 (s), 137.1 (s), 133.8 (s), 128.9 (s),
128.6 (t, J = 24.3 Hz), 127.9 (t, J = 6.5 Hz), 125.9 (s), 117.0 (s), 71.0 (s), 25.4 (s). HRMS
(ESI+): m/z calc’d for C24H14F17O5+: 705.0564. Found: 705.0570.
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2-Hydroxy-5-methyl-7-((4-(perfluorooctyl)benzyl)oxy)-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1-one (4.30m). A solution of tropolone 4.30l (50 mg, 0.071 mmol),
PyBOP (40.6 mg, 0.0781 mmol, 1.1 equiv.), and DIPEA (27.2 μL, 0.156 mmol, 2.2 equiv.) in
EtOAc (0.04 M, 1.67 mL) was stirred at room temperature for 20 min in a sealed tube reactor
(Biotage® microwave reaction vial, 2-5 mL). Piperidine (7.7 μL, 0.0781 mmol, 1.1 equiv.) was
then added to the sealed vessel, and the reaction mixture was subjected to microwave radiation at
85 ºC for 5 min. The reaction mixture was concentrated under reduced pressure and purified by
FSPE as described in Protocol A. The acetone layer was evaporated, producing a yellow solid.
The solid was washed with hexane (5 x 2 mL) and dried under vacuum to give 4.30m as a light
yellow solid (45.8 mg, 84% yield). MP = 183-186 ºC. IR (thin film, KBr): 3175 (br), 2942 (w),
2929 (w), 2861 (w), 1621 (m), 1568 (m), 1462 (m), 1450 (m), 1324 (m), 1202 (s), 1151 (s), 1135
(s), 1110 (s), 810 (m), 735 (m), 661 (m) cm-1. 1H NMR (400 MHz, CDCl3): δ 8.93 (bs, 1H),
7.63 (s, 4H), 7.17 (s, 1H), 7.16 (s, 1H), 5.36 (d, J = 12.8 Hz, 1H), 5.32 (d, J = 12.8 Hz, 1H),
3.84 – 3.75 (m, 1H), 3.69 – 3.61 (m, 1H), 3.27 – 3.13 (m, 2H), 2.34 (s, 3H), 1.76 – 1.62 (m, 4H),
1.60 – 1.43 (m, 2H).
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F NMR (376 MHz, CDCl3): δ -80.7 (t, J = 9.9 Hz, 3F), -110.7

(t, J = 14.4 Hz, 2F), -121.1 – -121.3 (m, 2F), -121.7 – -122.0 (m, 6F), -122.5 – -122.8 (m, 2F),
-125.9 – -126.3 (m, 2F). 13C NMR (100 MHz, CDCl3): δ 170.4 (s), 168.6 (s), 161.2 (s), 157.2
(s), 140.2 (s), 138.6 (s), 132.8 (s), 129.1 (t, J = 24.3 Hz), 127.6 (s), 127.5 (t, J = 6.5 Hz), 126.6
(s), 116.2 (s), 71.0 (s), 47.9 (s), 42.6 (s), 26.6 (s), 25.7 (s), 24.5 (s), 24.2 (s). HRMS (ESI+): m/z
calc’d for C29H23F17NO4+: 772.1350. Found: 772.1351.
6-Hydroxy-2-methyl-N-(naphthalen-1-ylmethyl)-5-oxo-4-((4-(perfluorooctyl)benzyl)oxy)
cyclohepta-1,3,6-triene-1-carboxamide (4.30n). A solution of tropolone 4.30l (51.7 mg,
0.0734 mmol), PyBOP (42 mg, 0.0807 mmol, 1.1 equiv.), and DIPEA (28.1 μL, 0.161 mmol,
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2.2 equiv.) in EtOAc (0.04 M, 1.67 mL) was stirred at room temperature for 20 min in a sealed
tube reactor (Biotage® microwave reaction vial, 2-5 mL). 1-Naphthylmethylamine (11.8 μL,
0.0807 mmol, 1.1 equiv.) was then added to the sealed vessel, and the reaction mixture was
subjected to microwave radiation at 85 ºC for 5 min. The reaction mixture was concentrated
under reduced pressure and purified by FSPE as described in Protocol A. The acetone layer was
evaporated, producing a yellow solid. The solid was washed with hexane (5 x 2 mL) and ACN
(5 x 2 mL) and dried under vacuum to give 4.30n as a light yellow solid (53.8 mg, 87% yield).
MP = 175-177 ºC. IR (thin film, KBr): 3239 (br), 3048 (w), 2923 (w), 1666 (m), 1541 (m),
1471 (m), 1398 (w), 1373 (w), 1325 (m), 1212 (s), 1199 (s), 1146 (s), 1112 (m), 945 (w), 788
(m), 658 (m) cm-1. 1H NMR (400 MHz, CDCl3): δ 8.10 (d, J = 8.1 Hz, 1H), 7.87 (d, J = 8.0 Hz,
1H), 7.81 (d, J = 8.1 Hz, 1H), 7.65 – 7.47 (m, 7H), 7.46 – 7.40 (m, 1H), 7.22 (s, 1H), 7.00
(s, 1H), 6.40 (bs, 1H), 5.15 (s, 2H), 5.01 (s, 2H), 2.34 (s, 3H).
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F NMR (659 MHz, CDCl3): δ

-80.7 (t, J = 9.4 Hz, 3F), -110.7 (t, J = 13.7 Hz, 2F), -121.2 (bs, 2F), -121.6 – -122.1 (m, 6F),
-122.7 (bs, 2F), -126.1 (bs, 2F). 13C NMR (100 MHz, CDCl3): δ 170.2 (s), 169.1 (s), 160.6 (s),
157.4 (s), 139.9 (s), 138.5 (s), 134.5 (s), 134.1 (s), 132.9 (s), 131.5 (s), 129.3 (s), 129.1
(t, J = 26.6 Hz), 129.1 (s), 127.5 (t, J = 6.4 Hz), 127.5 (s), 127.4 (s), 127.0 (s), 126.4 (s), 126.1
(s), 125.6 (s), 123.5 (s), 116.9 (s), 70.8 (s), 42.3 (s), 24.7 (s). HRMS (ESI+): m/z calc’d for
C35H23 F17NO4+: 844.1350. Found: 844.1353.
Synthesis of α-Hydroxytropolones:
2,7-Dihydroxy-4-methyl-5-phenylcyclohepta-2,4,6-trien-1-one (4.24a). FSPE Purification.
Tropolone 4.30a (50 mg, 0.068 mmol) and 33% HBr in acetic acid (197 μL) were placed in a
sealed tube reactor (Biotage® microwave reaction vial, 2-5 mL), and the reaction mixture was
heated to 120 ºC in silicon bath oil for 1 h. The reaction mixture was cooled to room
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temperature, quenched with phosphate buffer (pH 7, 0.1 M, 5 mL), and extracted with CHCl 3
(3 x 5 mL). The organic layer was evaporated under reduced pressure and purified by FSPE as
described in Protocol A. The 80% MeOH in H2O layer was concentrated to yield 4.24a as a
white solid (13.2 mg, 85% yield). The 1H NMR for 4.24a was consistent with previously
reported data.55 FLLE Purification, Protocol A. Tropolone 4.30a (50.5 mg, 0.0686 mmol) and
33% HBr in acetic acid (199 μL) were placed in a sealed tube reactor (Biotage® microwave
reaction vial, 2-5 mL), and the reaction mixture was heated to 120 ºC in silicon bath oil for 1 h.
The reaction mixture was cooled to room temperature, quenched with phosphate buffer (pH 7,
0.1 M, 5 mL), and extracted with CHCl3 (3 x 5 mL). The organic layer was dried over Na2SO4,
filtered, and evaporated under reduced pressure to give a crude oil. The residue was taken up in
ACN (2 mL) and washed with 50% HFE-7100 in perfluoromethylcyclohexane (5 x 2 mL). The
ACN layer was concentrated to yield 4.24a as a brown oil (15.5 mg, >95% yield). The 1H NMR
for 4.24a was consistent with previously reported data.55
4-([1,1'-Biphenyl]-3-yl)-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trien-1-one (4.24j). FSPE
Protocol B. Compund 4.28j (36.1 mg, 0.0443 mmol), phenyl boronic acid (54 mg, 0.443 mmol,
10 equiv.), water soluble SPhos (23 mg, 0.0443 mmol, 1 equiv.), K2CO3 (61.2 mg, 0.443 mmol,
10 equiv.), Pd(OAc)2 (5 mg, 0.0222 mmol, 0.5 equiv.) and 33% ACN in H2O (0.01 M, 4.5 mL)
were placed in a sealed tube reactor (Biotage® microwave reaction vial, 2-5 mL), and the
reaction mixture was heated to 50 oC in silicon bath oil for 5 h. The reaction mixture was cooled
to room temperature and immediately loaded to a Biotage® SNAP Ultra 10 g cartridge that was
filled with SiliBond® Tridecafluoro silica gel (4 g) and preconditioned with 30% ACN in H2O.
Any remaining residue in the reactor was loaded onto the column with CHCl 3, and the
nonfluorous material was provided by elution with ACN in H2O (0% ACN/H2O to 70%
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ACN/H2O gradient over 12 column volumes) and MeOH in H2O (80% MeOH/H2O over
3 column volumes). The fluorous component was obtained by elution with MeOH (100% MeOH
over 5 column volumes) and the resulting fractions were then concentrated, giving 4.28o as a
yellow oil (26.4 mg, 73% crude yield).
To a solution of oxabicycle 4.28o (26.4 mg, 0.0325 mmol) in CH2Cl2 (0.1 M, 325 μL)
was added trifluoromethanesulfonic acid (11.5 μL, 0.13 mmol, 4 equiv.). The reaction mixture
was allowed to stir for 30 minutes, after which time it was quenched with phosphate buffer
(pH 7, 0.1 M, 5 mL) and extracted with CHCl 3 (3 x 5 mL). The organic layer was dried over
Na2SO4, filtered, and concentrated under reduced pressure. The crude mixture was then
dissolved in 33% HBr in acetic acid (100 μL) and heated to 120 ºC for 1 h in a sealed tube
reactor (Biotage® microwave reaction vial, 2-5 mL). The reaction mixture was cooled to room
temperature, quenched with phosphate buffer (pH 7, 0.1 M, 5 mL), and extracted with CHCl 3
(3 x 5 mL). The organic layer was then dried over Na 2SO4, filtered, and concentrated to give a
crude oil. The residue was purified by FLLE according to Protocol A, giving 4.24j as a brown oil
(8.9 mg, 90% yield over two steps). IR (thin film, KBr): 3248 (br), 3059 (w), 3033 (w), 2928
(w), 2854 (w), 1525 (s), 1477 (m), 1450 (m), 1386 (s), 1277 (s), 1231 (s), 1131 (m), 1093 (m),
908 (m), 758 (s), 698 (m) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.65 – 7.59 (m, 4H), 7.55 (s,
1H), 7.54 – 7.42 (m, 4H), 7.40 – 7.34 (m, 1H), 7.24 – 7.20 (m, 1H), 2.31 (s, 3H).
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C NMR

(100 MHz, CDCl3): δ 167.3, 157.9, 156.6, 144.2, 143.8, 141.8, 140.6, 139.2, 129.2, 129.0,
127.8, 127.3, 127.3, 127.2, 126.6, 124.5, 124.3, 26.6. HRMS (ESI+): m/z calc’d for C20H17O3+:
305.1172. Found: 305.1176.
2,7-Dihydroxy-4-methyl-5-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1-one (4.24m).
Method A. To a solution of oxabicycle 4.28m (39.4 mg, 0.0511 mmol) in CH2Cl2 (0.1 M,
511 μL) was added trifluoromethanesulfonic acid (18 μL, 0.204 mmol, 4 equiv.). The reaction
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mixture was allowed to stir for 30 minutes, after which time it was quenched with phosphate
buffer (pH 7, 0.1 M, 5 mL) and extracted with CHCl 3 (3 x 5 mL). The organic layer was dried
over Na2SO4, filtered, and concentrated under reduced pressure producing a brown residue. The
crude mixture was then dissolved in 33% HBr in acetic acid (150 μL), and heated to 120 ºC for
1 h in a sealed tube reactor (Biotage® microwave reaction vial, 2-5 mL). The reaction mixture
was cooled to room temperature, quenched with phosphate buffer (pH 7, 0.1 M, 5 mL), and
extracted with CHCl3 (3 x 5mL). The organic layer was then dried over Na 2SO4, filtered, and
concentrated to give a crude oil. The residue was purified by FLLE according to Protocol A,
giving 4.24m as a brown oil (10.4 mg, 77% yield over two steps). Method B. Tropolone 4.30m
(40 mg, 0.0518 mmol) and 33% HBr in acetic acid (150 μL) were placed in a sealed tube reactor
(Biotage® microwave reaction vial, 2-5 mL), and the reaction mixture was heated to 120 ºC in
silicon bath oil for 1 h. The reaction mixture was cooled to room temperature, quenched with
phosphate buffer (pH 7, 0.1 M, 5 mL), and extracted with CHCl 3 (3 x 5 mL). The organic layer
was dried over Na2SO4, filtered, and evaporated under reduced pressure to give a crude oil. The
residue was purified by FLLE according to Protocol A, giving 4.24m as a brown oil (12.5 mg,
92% yield). Characterization of 4.24m. IR (thin film, KBr): 3246 (br), 2940 (s), 2859 (m), 1627
(s), 1541 (s), 1446 (s), 1389 (s), 1353 (s), 1265 (s), 1232 (s), 1136 (s) 1075 (m), 1026 (m), 912
(m), 811 (m), 730 (s) cm-1. 1H NMR (400 MHz, CDCl3): δ 7.47 (s, 1H), 7.27 (s, 1H),
3.86 – 3.77 (m, 1H), 3.70 – 3.62 (m, 1H), 3.25 – 3.13 (m, 2H), 2.41 (s, 3H), 1.77 – 1.44 (m, 6H).
13

C NMR (100 MHz, CDCl3): δ 168.7, 168.2, 158.3, 157.8, 137.5, 137.0, 124.3, 118.6, 47.9,

42.7, 26.5, 25.7, 24.5, 24.1. HRMS (ESI+): m/z calc’d for C14H18NO4+: 264.1230. Found:
264.1230.
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4,6-Dihydroxy-2-methyl-N-(naphthalen-1-ylmethyl)-5-oxocyclohepta-1,3,6-triene-1carboxamide (4.24n). Tropolone 4.30n (53 mg, 0.0628 mmol) and 33% HBr in acetic acid
(185 μL) were placed in a sealed tube reactor (Biotage® microwave reaction vial, 2-5 mL), and
the reaction mixture was heated to 120 ºC in silicon bath oil for 1 h. The reaction mixture was
cooled to room temperature, quenched with phosphate buffer (pH 7, 0.1 M, 5 mL), and extracted
with CHCl3 (3 x 5 mL). The organic layer was dried over Na2SO4, filtered, and evaporated under
reduced pressure to give a crude oil. The residue was purified by FLLE according to Protocol A,
giving 4.24n as a brown oil (18.8 mg, 89% yield). IR (thin film, KBr): 3263 (br), 3060 (m),
2928 (m), 1697 (s), 1640 (s), 1536 (s), 1512 (s), 1441 (m), 1397 (s), 1248 (s), 1144 (m) 1091
(m), 1055 (m), 903 (w), 780 (m), 726 (w) cm-1. 1H NMR (400 MHz, Acetone): δ 8.28
(d, J = 8.3 Hz, 1H), 8.02 (bs, 1H), 7.96 (d, J = 8.0 Hz, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.64 – 7.46
(m, 4H), 7.42 (s, 1H), 7.34 (s, 1H), 5.07 (d, J = 5.7 Hz, 2H), 2.42 (s, 3H). 13C NMR (100 MHz,
Acetone): δ 169.9, 169.1, 159.7, 158.3, 138.7, 138.0, 135.2, 134.9, 132.5, 129.6, 129.1, 127.6,
127.2, 126.8, 126.3, 124.7, 124.3, 119.9, 42.1, 24.3. HRMS (ESI+): m/z calc’d for C20H18NO4+:
336.1230. Found: 336.1233.

210

Figure 4.4. 1H NMR spectrum of compound 4.28a (Method A) in CDCl3.

211

Figure 4.5. 1H NMR spectrum of compound 4.28a (Method B) in CDCl3.

212

Figure 4.6. 19F NMR spectrum of compound 4.28a in CDCl3.

213

Figure 4.7. 13C NMR spectrum of compound 4.28a in CDCl3.

214

+

Figure 4.8. 1H NMR spectrum of compounds 4.28a and 4.29a (prior to FSPE) in CDCl3.
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Figure 4.9. 1H NMR spectrum of compound 4.29a (after FSPE) in CDCl3.
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Figure 4.10. 1H NMR spectrum of compound 4.28a (after FSPE) in CDCl3.
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Figure 4.11. 1H NMR spectrum of compound 4.28j in CDCl3.
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Figure 4.12. 19F NMR spectrum of compound 4.28j in CDCl3.

219

Figure 4.13. 13C NMR spectrum of compound 4.28j in CDCl3.
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Figure 4.14. 1H NMR spectrum of recovered alkyne 4.31 in CDCl3.

221

Figure 4.15. 1H NMR spectrum of compound 4.28o in CDCl3.

222

Figure 4.16. 1H NMR spectrum of compound 4.28k in CDCl3.

223

Figure 4.17. 19F NMR spectrum of compound 4.28k in CDCl3.

224

Figure 4.18. 13C NMR spectrum of compound 4.28k in CDCl3.

225

Figure 4.19. 1H NMR spectrum of compound 4.28l in CDCl3.

226

Figure 4.20. 19F NMR spectrum of compound 4.28l in CDCl3.

227

Figure 4.21. 13C NMR spectrum of compound 4.28l in CDCl3.

228

Figure 4.22. 1H NMR spectrum of compound 4.28m in CDCl3.

229

Figure 4.23. 19F NMR spectrum of compound 4.28m in CDCl3.

230

Figure 4.24. 13C NMR spectrum of compound 4.28m in CDCl3.

231

Figure 4.25. 1H NMR spectrum of compound 4.30a in CDCl3.

232

Figure 4.26. 19F NMR spectrum of compound 4.30a in CDCl3.

233

Figure 4.27. 13C NMR spectrum of compound 4.30a in CDCl3.

234

Figure 4.28. 1H NMR spectrum of compound 4.30l in acetone-d6.

235

Figure 4.29. 19F NMR spectrum of compound 4.30l in acetone-d6.

236

Figure 4.30. 13C NMR spectrum of compound 4.30l in acetone-d6.

237

Figure 4.31. 1H NMR spectrum of compound 4.30m in CDCl3.

238

Figure 4.32. 19F NMR spectrum of compound 4.30m in CDCl3.

239

Figure 4.33. 13C NMR spectrum of compound 4.30m in CDCl3.

240

Figure 4.34. 1H NMR spectrum of compound 4.30n in CDCl3.

241

Figure 4.35. 19F NMR spectrum of compound 4.30n in CDCl3.

242

Figure 4.36. 13C NMR spectrum of compound 4.30n in CDCl3.

243

Figure 4.37. 1H NMR spectrum of compound 4.24a (after FSPE) in CDCl3.

244

Figure 4.38. 1H NMR spectrum of compound 4.24a (after FLLE) in CDCl3.

245

Figure 4.39. 1H NMR spectrum of compound 4.24j in CDCl3.

246

Figure 4.40. 13C NMR spectrum of compound 4.24j in CDCl3.

247

Figure 4.41. 1H NMR spectrum of compound 4.24m (Method A) in CDCl3.

248

Figure 4.42. 1H NMR spectrum of compound 4.24m (Method B) in CDCl3.

249

Figure 4.43. 13C NMR spectrum of compound 4.24m in CDCl3.

250

Figure 4.44. 1H NMR spectrum of compound 4.24n in acetone-d6.

251

Figure 4.45. 1H NMR spectrum of compound 4.24n in acetone-d6.
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